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CHAPTER I 
 
INTRODUCTION 
 
With cancer encompassing a range of disease states and phenotypes, identifying 
effective or non-effective treatments early, accurately, and non-invasively is essential 
such that the course of treatment can be modified if needed. Thus, using various imaging 
techniques such as X-ray mammography, positron emission tomography (PET), and 
magnetic resonance imaging (MRI) has become a popular option for the ability to non-
invasively monitor changes during treatment. This work will discuss two types of cancer 
imaging techniques, and the importance they have to several classes of drug treatment 
regimens. Additionally, this work will further optimize and identify errors in current 
protocols used in preclinical studies of drug efficacy. These optimized protocols will then 
be used to assess the efficacy of a novel anti-cancer treatment early in the course of 
therapy; and finally, the relationship of two imaging biomarkers frequently used in 
monitoring cancer therapy will be assessed and compared to histology.  
The goal of Aim 1 is to assess the error in parameters extracted from dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) modeling when using a 
vascular input function (VIF) derived from a population average versus those 
extracted with an individually measured VIF in mice.  The measurement of a VIF 
needed to drive pharmacokinetic models requires high temporal resolution and the 
presence of a major vessel within the field of view. In order to achieve these 
requirements, signal is sacrificed, and coverage and location of the region of interest is 
2 
 
limited. VIF measurements were obtained in a cohort of mice using two different contrast 
agents of varying molecular weight in order to assess the error in the kinetic parameters 
within the tumor associated with using a population VIF or individual VIF.   
The goal of Aim 2 is examine a novel Jak2 inhibitor with both DCE-MRI and 
diffusion-weighted MRI (DW-MRI) to determine if these imaging techniques can be 
used to assess preclinical efficacy. Both DCE-MRI and DW-MRI have been shown to be 
informative when monitoring treatment and determining drug efficacy. Using a novel 
drug that functions as a Jak2 inhibitor, animals were imaged using DCE-MRI and DW-
MRI at multiple time points to assess the effectiveness of using DCE-MRI and DW-MRI 
as early response metrics 
The goal of Aim 3 is to compare the parameters found using DCE-MRI with 
similar measures determined from DW-MRI both before and during the course of 
therapy.  Apparent diffusion coefficient (ADC) maps obtained from DW-MRI have been 
shown to be a metric of cellularity in tumors. Since one of the parameters obtained from 
DCE-MRI studies is the fraction of extravascular-extracellular space (ve), maps of ADC 
and ve should be directly proportional to each other in that they both change positively in 
response to reduced cell density. However, previous literature suggests that the 
relationship between these parameters may be more complex in response to treatment. 
The relationship between these two parameters has been assessed on a spatial and 
histological scale using two treatment regimens. 
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CHAPTER II 
 
MAGNETIC RESONANCE IMAGING 
 
Fundamentals of Magnetization and Relaxation 
In the following work, magnetic resonance imaging (MRI) is the primary tool used to 
probe various aspects of cancer and to monitor cancer treatment. An abbreviated 
description of nuclear magnetic resonance (NMR) and MRI is provided for clarity, but 
more details can be found in reference (1). 
The signal from MRI is derived from nuclear magnetic properties of particular nuclei 
such as 
1
H, 
13
C, and 
19
F, for example. This work exclusively describes proton or 
1
H MRI 
but non-proton MRI is discussed in references (2,3). These nuclei possess property 
magnetic moment that has both magnitude and direction, illustrated in Fig. II-1 (a).  
 
When no magnetic field is present, these magnetic dipoles, or “spins,” have random 
alignment; however, when an external magnetic field is present, these spins will align 
either parallel or anti-parallel to the field, shown in Fig. II-1 (b). These protons not only 
 
Fig. II-1.  Spin Alignment in a Magnetic Field. Panel a illustrates nuclei as magnetic 
dipoles, or “spins,” in random alignment  while panel b shows that the nuclei align 
parallel or anti-parallel when an external magnetic field B is introduced. 
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align with the external magnetic field B, but they also precess about the axis B is applied. 
The frequency at which they precess is known as the Larmor frequency (ωo). The Larmor 
frequency is directly proportional to the gyromagnetic ratio, γ (approximately 42.6 
MHz/T for 
1
H), and the strength of the external magnetic field (B) and can be described 
as 
Bγω0 . (II-1) 
On a more macroscopic level, the individual nuclei or spins can be summed to 
produce a net magnetization vector (M) that can describe the system as in Fig. II-2 (a). At 
equilibrium, the magnetization vector lies parallel to the main magnetic field, B. The bulk 
magnetization align with and precess about the external magnetic field B.  
 
By introducing radiofrequency (RF) energy at the Larmor frequency in a form such as a 
pulsed B1 field along the x-axis, the vector is nutated away from a direction parallel to the 
external magnetic field as shown in Fig. II-2 (b). If the applied B1 pulse stops, the net 
magnetization (M) will slowly “relax” back to equilibrium. The process of M returning 
back to alignment with the external magnetic field B is known as longitudinal relaxation 
and is characterized by a time constant known as T1( ≡ 1/R1). This longitudinal relaxation 
 
Fig. II-2.  The “spins” are summed to form a net magnetization vector (M) that, at 
equilibrium, aligns with the magnetic field, B, as shown in panel (a). As RF energy 
(B1) is introduced at the Larmor frequency, M will tip away from equilibrium as 
shown in panel (b) while panel (c) shows that the vector M also precesses at the 
Larmor frequency forming a cone of precession. 
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is not the only type of relaxation occurring with this system. As the net magnetization M 
is tipped away from the direction parallel to the main magnetic field, the spins are aligned 
or “in phase.” Instead of the net magnetization “relaxing” along the direction of the 
magnetic field, M will precess around the field direction, similar to a spinning gyroscope. 
Thus, the spins exhibit more of a characteristic cone of precession around the 
magnetization vector M as represented in Fig. II-2 (c).   
At equilibrium, these spins precess at a frequency affected by the local and global 
environmental magnetic fields. To clarify, Fig. II-3 shows the magnetization vector M in 
a plane perpendicular to the main magnetic field, also known as the transverse plane. The 
spins precess at different frequencies until the B1 pulse is introduced which aligns the 
spins as shown in Fig. II-3 (a).  
 
With no RF energy input, the spins will dephased based on their independent 
precession frequency as shown in Fig. II-3 (b) and (c); consequently, the spins dephase at 
a rate known as T2. The effects of these relaxation properties can be described in a series 
of equations known as the Bloch equations (4). The change in the net magnetization M as 
 
Fig. II-3.  In the transverse plane (perpendicular to the magnetic field B), spins will be 
in phase as they precess at the Larmor frequency as shown in panel (a). Once the B1 
pulse is removed, the spins begin to dephase according to local magnetic field 
variations at a rate of T2 shown in panel (b) and (c). 
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it experiences a torque associated with the pulsed magnetic field B1 and the effects of T1 
and T2 relaxation (noted as R for relaxation) can be described by 
))(( 0M-t -γ
dt
d
MRBM
M
1 . (II-2) 
Since T1 and T2 effect the magnetization vector in different directions, R must be broken 
down along the three orthogonal axes to reflect the transverse relaxation occurring the x-y 
plane and longitudinal relaxation occurring along the z-direction: 
)(
2T
- -γ
dt
d x
yzzy
x MBMBM
M
,  (II-3) 
)(
2T
- -γ
dt
d y
xzzx
y M
BMBM
M
, and (II-4) 
)(
1
0
T
M
- -γ
dt
d z
xyyx
z MBMBM
M
. (II-5) 
These equations can be integrated and solved by the Laplace transform, for example, 
to obtain: 
2t/Te0t )()( xyxy MM   and  )()()(
1t/Te10t zz MM .  (II-6/II-7) 
By manipulating the timing and B1 pulses, sequences can be developed to better exploit 
these relaxation properties to differentiate between tissue types and diseased states. The 
two most common MR experiments are the spin echo or gradient echo acquisitions.  A 
simple spin-echo sequence is described as a pulse that reflects a 90° tip away from the z 
axis and then a 180° refocusing pulse to “reverse” the dephasing spins shown in Fig. II-3 
(c) so that they will partially rephrase, causing a signal echo at a time TE, or echo time. 
The change in signal (S), which is proportional to the net magnetization described above, 
can be characterized by the following equation: 
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2TE/T1TR/TTTETR
0 eee1SS ]2[
)1/)2/( ,  (II-8) 
where S0 is the initial signal related to the net magnetization and TR is the repetition time 
between 90° pulses.  
The second common NMR experiment is based on administering a pulse at an 
arbitrary flip angle, α, and using magnetic gradients to rephase the signal. The gradient 
echo equation describes the change in signal by  
))((
)()(
1TR/T
*
2TE/T1TR/T
0
eαcos1
eαsine1
SS ,  (II-9) 
where T2
*
 represents the combination of T2 and T2´, a quantity that represents sample and 
field homogeneity. For the purpose of the work presented in this dissertation, it is 
assumed that there is a relatively homogeneous external field such that T2
*
 ≈ T2. The 
parameters of TR, TE, and α can be manipulated to weight the image contrast based on 
either T1 or T2 relaxation. For example, the acquisition can be weighted for T1 relaxation 
by making the TR short relative to T1 and TE very short (much shorter than the T2 of the 
tissue of interest); thus, the T2 relaxation component will become negligible. The work 
presented here focuses primarily on T1 relaxation so for the sake of brevity, T2 relaxation 
measurements will be omitted but further discussion can be found in reference (1). 
 
Image Reconstruction 
Determining the origin, in three dimensional space, of the signals discussed in the 
previous section is required in order to form an image; spatial encoding is the process by 
which these signals are mapped into coordinates in space. First, a “slice select” magnetic 
gradient is used to change the precession frequency of the spins along the slice selection 
axis (e.g., the z-axis). By having these precession frequencies vary in a known spatial 
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coordinate system, the excitation pulse can then be “tuned” to perturb spins at a particular 
location along the z-axis; thus, the selected slice will be uniquely identified. Additional 
gradients can be used to identify the origin of a signal within the selected slice/plane. A 
phase encode gradient is applied, essentially assigning “columns” of spins with phases 
varying across a field of view. And finally, a frequency-encoding gradient is applied. 
This gradient divides the image space into “rows” with varied precession frequencies. 
Now, the signal extracted from an MRI experiment can be decomposed using a 2D 
Fourier transform analysis, allowing the frequency and phase contributions assigned by 
the spatially varied gradients to be separated and form an image.  
 
Measuring T1 
As discussed above, once magnetization has been tipped into the transverse plane, it 
will regrow along the z-axis back to equilibrium at a rate of R1 (≡ 1/T1). There are several 
methods for determining the T1 of tissue (5). For example, by collecting data at multiple 
TR or flip angle (α) values via either a spin echo or gradient echo experiment, Eqn. (II-8) 
or Eqn. (11-9) can be fit to the data to estimate T1 for a particular sample. One technique 
for a robust estimation of T1 is an inversion recovery sequence in which the net 
magnetization is flipped 180° and is sampled along the regrowth at different times, called 
inversion times, TI. After the inversion pulse the signal (S) can be described as 
)( 1
TR/T1TI/T
0 ee21SS ,  (II-10) 
where S0 and S are the signal intensities at baseline and at the inversion time, 
respectively. The resulting absolute value of the signal at each inversion time is 
graphically shown in Fig. II-4.  After acquisition, the data is fit to Eqn. (11-10), 
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represented by the solid line in the figure. This fit produces an estimation of T1 for each 
voxel to yield a T1 map of the tissue of interest. 
 
 
Contrast Agents 
Unlike X-ray or CT contrast agents (CAs) that provide a direct effect on the image 
signal, MRI contrast agents indirectly alter the signal via influencing the relaxation of the 
hydrogen nuclei. Simply put, MRI contrast agents work by shortening the native 
relaxation times of the tissue(s) they penetrate, thereby changing the R1 of that tissue. In 
order to accomplish this task, MRI CAs must be designed to strongly interact with the 
spin, in this case, the hydrogen nuclei. One characteristic of an ideal MRI contrast agent 
is a high number of unpaired electrons. Unpaired electrons have a much stronger 
magnetic moment than that of the nuclei; thus, MRI CAs are typically developed by 
using elements with many unpaired electrons to dominate the magnetic moment produced 
 
Fig. II-4.  The signal can be sampled at multiple inversion times (•) and fit to Eq. II-10 
(solid line) to obtain T1 measurements. 
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by the nuclei. The two CAs discussed in this Dissertation use chelated gadolinium (Gd), 
which has seven unpaired electrons (6).  
In addition to unpaired electrons, another desirable characteristic of an MRI contrast 
agent is an appropriate correlation time. Molecules in a liquid are free to rotate, and the 
inverse of the frequency at which they rotate is known at as the correlation time. 
Molecules that have an optimum rotation can interact with surrounding molecules more 
frequently causing the relaxation times to change. For T1 relaxation, molecules rotating at 
the Larmor frequency have the maximum opportunity to interact with neighboring 
molecules. Since the rotation frequency in a liquid is typically faster than the Larmor 
frequency, the size of the contrast agent increases the correlation time for a more efficient 
interaction. The two contrast agents used in this work have different molecular sizes, 
directly responsible for the difference in relaxivities (7,8). The relaxivity of a contrast 
agent describes how the R1 relaxation changes with respect to concentration, and this is 
dependent on the type of agent used as well as field strength at relatively low 
concentrations (like that in tissue). By using the baseline relaxation measurement, R10, 
and the known relaxivity of the agent (r), the concentration of contrast agent can be 
determined by (9) 
101 RCArR ][ .   (II-11) 
The relaxivity of an agent describes the efficacy of an agent to induce a change in 
relaxation; therefore, the higher the relaxivity, the better contrast between the 
surrounding tissue and tissue affected by the agent.  
Gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) is a small (~0.6 kDa) 
hydrophilic, barrier-limited molecule that has strong paramagnetic properties allowing it 
11 
 
to successfully change the relaxation rates of surround tissue. Gd-DTPA has high in vivo 
stability, rapid clearance, and minimal toxicity; these characteristics have allowed Gd-
DTPA to be a frequently used CA in the clinic (10).  A contrast agent called P846 
(Guerbet, Aulnay-sous-Bois, France) has a molecular weight of approximately 3.54 kD 
and consists of a single Gd ion in a macro-cyclic 3-armed chelate. This larger contrast 
agent has a higher correlation time, yielding a higher relaxivity relative to Gd-DTPA. 
Additionally, the size of this CA gives rise to different pharmacokinetic properties; as 
shown in Chapter VI, this property gives rise to an elongated contrast enhancement 
period as it is less permeable than the smaller agent (11).  
The subsequent studies in Chapters V through VIII will utilize these properties of 
MRI, relaxation, and MRI contrast agents to examine properties that distinguished 
diseased tissue from normal tissue. While MRI is applicable to a wide range of disease 
states, this work will focus specifically on the vascular and cellular aspects of cancer.  
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CHAPTER III 
 
BIOLOGICAL BACKGROUND OF CANCER 
 
Introduction 
While cancer is a very complex disease state, there are several “hallmarks” that can 
be generalized across cancer type or tumor model. These attributes are discussed in 
greater detail in references (1,2) but, this work will focus on two specific traits: cellularity 
and angiogenesis. 
Cellularity 
One fundamental characteristic of cancer cells is the ability to proliferate unregulated, 
typically resulting in a very dense tumor mass that can spread depending on the 
aggressive nature of the cancer. There are several aspects that contribute to the 
unregulated proliferation as documentd in established cancer cell lines. First, cancer cells 
adapt to produce and sustain growth signals despite environmental factors. It has been 
shown that cancer cells can generate or mimic growth signals independently. An example 
of this is the ability of glioblastomas and sarcomas to produce platelet-derived growth 
factor (PDGF) and tumor growth factor α (TGFα), both of which blood vessel formation 
and cell growth regulation (1). Surface receptors for growth factors have also been shown 
to be upregulated in cancer. This upregulation in receptors tends to make tumor cells 
hypersensitive to potentially low to normal amounts of circulating growth factors; 
overexpression of the HER2/neu receptors, which activate proliferative molecular 
pathways, have been noted in some stomach and mammary cancer cell lines (3). With 
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these and other mechanisms, cancer cells can sustain activation of proliferative pathways 
without input from the surrounding environment. 
 To complement the independent generation of pro-growth factors, tumor cells have 
developed mechanisms to becoming insensitive to anti-growth factors (4) and avoid 
terminal differentiation (5). Anti-growth factors drive cells out of an active proliferative 
cycle into a state of quiescence. For example. retinoblastoma protein (pRb) is strongly 
linked to anti-proliferative signal pathways; when pRb is in a hypophosphorylated state, 
it blocks proliferation by sequestering E2F transcription factor, which is responsible for 
gene expression associated with transitioning from G1 into S phase of the cell cycle (4). 
It has been shown that if the pRb pathway is perturbed, E2F is released, allowing the cells 
to proliferate, insensitive to anti-growth feedback. TGFβ, for example, is a small 
signaling molecule that has been shown to prevent phosphorylation of pRb that would 
render it inactive, thereby reinforcing proliferative effects (6).  
Additionally, cancer cells develop the ability to evade programmed cell death, or 
apoptosis. Briefly, most apoptotic signaling funnels through the mitochondria, where a 
potent catalyst of apotosis, cytochrome C, is released (7). Once cytrochrome C is 
released, it can stimulate intracellular proteases known as caspases (8). These caspases 
are responsible for executing a sequence that leads to cell death. Mutations in the 
apoptotic signaling pathways which activate cytochrome C can lead to anti-apoptotic 
affects. For example, bcl-2, an anti-apoptotic protein, is upregulated in follicular 
lymphoma, leading to the improved survival of lymphocytes. (9,10).  
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Increased proliferation and survival are not the only mechanisms by which cancer 
cells flourish; the ability to continuously proliferate is not governed by growth factors 
alone. Normal cells typically have a terminal number of replications within a lifespan 
before entering a state of senescence. A phenotype of cancer cells that differentiates them 
from normal cells is the ability to bypass the state of senescence and become essentially 
“immortalized,” proliferating limitlessly (11). With cancer cells developing such 
phenotypes, monitoring the cellularity of a tumor cite has become an important 
biomarker for aggressive tumors. Additionally, this attribute has become a target for 
therapy as well as a useful biomarker for imaging, discussed in subsequent chapters.   
 
Angiogenesis 
Another fundamental “hallmark” of cancer is the ability to recruit and sustain a 
vascular network to allow for a continuous supply of nutrients. In order for a tumor to 
grow beyond approximately 1-2 mm
3
, a tumor must recruit and form new vasculature as 
it can no longer rely on the passive diffusion of nutrients (12). During the process known 
as angiogenesis, several growth factors, including vascular endothelial growth factor 
(VEGF) are secreted to promote the migration of endothelial cells to the site. In 
particular, VEGF has been shown to be a rate-limiting step in angiogenesis, making it a 
target for various therapies as well. VEGF binds to two primary endothelial receptors 
known as Flt-1 (VEGFR-1) and KDR (VEGF-R2). Via these receptors, various pathways 
are stimulated that promote neovascularization in tumors including endothelial cell 
migration and proliferation (13), endothelial cell precursor recruitment (14), formation of 
capillary tubes (15) and permeability enhancement (16). However, the vessels produced 
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from pathological angiogenesis differ from that of normal vasculature. Normal 
vasculature is arranged as a progression from large arteries feeding into smaller 
arteries/arterioles which terminate at the capillary bed. From the capillary bed, venules 
carry the deoxygenated blood to small veins which empty into larger primary veins. 
During tumor angiogenesis, the imbalance between anti-angiogenic and angiogenic 
factors can lead to abnormal vasculature formation. Tumor vasculature has been reported 
to be leaky and poorly constructed with tortuous topology containing incomplete vessels 
(12,17,18).  
 The importance of tumor angiogenesis has led to a number of drugs developed to 
inhibit the growth of cancer via disruption of angiogenesis. The goal of these so-called 
anti-angiogenic drugs is to essentially cut off the development of an adequate blood 
supply, stunting tumor growth.  
 
Treatment 
As mentioned, numerous anti-cancer treatments and therapies have been developed 
that target the various cancer-specific (and even many nonspecific) characteristics. Below 
are discussed three categories of treatment: cytotoxic drugs, vasculature-targeted drugs, 
and a novel class of Jak2 inhibitors.  
 
Cytotoxic Drugs 
Cytotoxic treatments have been available in the clinic for several decades. This 
classification of drug typically attacks or disrupts mitotic function of neoplastic cells, 
thereby inducing apoptosis. Cytotoxic therapies interfere with cell proliferation by 1) 
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damaging DNA within the cell, causing cytotoxicity, 2) interfering with basic cellular 
metabolites such as enzymes used in the formation of nucleotides, or 3) inhibiting spindle 
formation during cell division. Doxorubicin is an example of a cytotoxic chemotherapy 
drug that acts by intercalating DNA and by inhibiting macromolecular biosynthesis. This 
process inhibits DNA unwinding and thereby hinder transcription (19,20). Methotrexate 
acts as a folate antagonist that inhibits enzymes involved in the formation of nucleotides 
(21). Another clinically-used cytotoxic therapy, paclitaxel, targets microtubule formation 
without which the cell cannot divide (22,23). While these therapies are commonly used in 
the clinic, they are not necessarily targeted to only tumor cells, and the side effects 
involve toxicity to other organs or systems that have high cell turnover such as hair 
follicles and intestinal lumen. Thus, targeting therapies to tumor-specific phenotypes has 
become an important area of research over the past several decades (24). 
 
Vasculature-Targeted Drugs 
Within the realm of “targeted” therapies, there are two classes that target the 
vasculature of the tumor system: anti-vascular and anti-angiogenic drugs. Anti-vascular 
drugs target the vascular endothelium; the vascular endothelium is highly proliferative 
and a class of tubulin-binding microtubule-depolymerizing agents has been developed to 
cause the collapse of mature tumor vessels. For example, combretastatins, a subclass of 
tubulin-binding agents, have been used widely in the clinic (25,26)   Anti-angiogenic 
drugs specifically target angiogenic pathways, ultimately inhibiting tumor 
neovascularization. Frequently, receptors and receptor tyrosine kinases such as vascular 
endothelial growth factor (VEGF) receptor, FLT1, PI3 kinase, and HIF are targeted by 
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these drugs because they are included in pathways that contribute to angiogenesis. 
Bevacizumab, ZD6474, SU11248, vatalanib, and AGM-1470 are several agents that 
serve as anti-angiogenic therapies (27). Recentin is a well-characterized anti-angiogenic 
drug that has been shown to reduce vascular density and stunt tumor growth reliably on 
the Calu-6 tumor lines.  Otherwise known as AZD 2171 (4-[(4-Fluoro-2-methyl-1H-
indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline), Recentin has a 
molecular weight of 450.51 D. This drug acts as a potent inhibitor of KDR tyrosine 
kinase thereby inhibiting VEGF induced signaling pathways in endothelial cells. In a 
comprehensive investigation into the efficacy of AZD 2171, Wedge, et al, compared 
AZD 2171 activity with other well known angiogenesis inhibitors both in vitro and in 
vivo (28). Not only was AZD 2171 found to be a potent inhibitor of KDR, it was shown 
to inhibit endothelial cell and tumor cell proliferation in a broad spectrum of human 
tumor models. Specifically, 6.4 ± 0.6 μmol/L of AZD 2171 were required to halt 
proliferation of the Calu-6 lung tumor cell line.  
 
Jak2 Inhibitor Drugs 
Other signal transduction pathways have also become a target for cancer therapies. 
Some of these pathways include downstream effects that offer a combination of anti-
anagiogenic, pro-apoptotic, and/or anti-proliferative consequences (24).  An example of 
this type of targeted therapy is a novel class known as Jak2 inhibitors. The Janus family 
kinases (Jak) are fundamental to mediating activation of signal transducers and activator 
of transcription (Stat) proteins. Stat proteins are responsible for mediating cytokine and 
growth factor responses. Over the past two decades, it has been shown that persistent 
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activation of Stat3 is found in a wide variety of human cancer cell lines (29), and that 
aberrant Stat3 activation is necessary for some cancer cell lines to survive (30,31). Stat3 
activation has been implicated in numerous survival and proliferative pathways, and 
blocking Stat3 has shown increased apoptosis induction (32) and decreased proliferation 
(30,33). In addition to implications in the upregulation of survival and proliferative 
pathways, it has been reported that persistent activation of Stat3 directly targets VEGF 
(32), one of the most potent angiogenesis-inducing signaling factors. Stat3 acts to direct 
transcriptional activation of VEGF, as well as having downstream effects that, when 
inhibited, may slow HIF1 activation, which is another upregulator of VEGF (34).  
A selective Jak2 small-molecule inhibitor, AZD 1480, has been shown to actively 
suppress the role of Stat3 in tumorgenesis. Tumor growth in multiple cell lines has been 
stunted at various doses. Additionally, Stat3 expression was reduced significantly in 
tumor tissues treated with the AZD 1480 (35). In unpublished data, mean vessel density 
was also significantly reduced in murine xenografts relative to vehicle controls. 
 
Conclusion 
Thus, as more and more progress is made in understanding molecular and 
physiological “hallmarks” of cancer, specificity and efficacy of treatments will continue 
to improve. To complement these targeted drugs, it is important to have specific metrics 
for monitoring the efficacy of new treatments that may similarly affect these aspects of 
cancer. Imaging has become a standard of care for non-invasively monitoring the efficacy 
of such drugs. For example, an imaging technique sensitive to cellular changes would be 
useful in monitoring cytotoxic or Jak2-inhibiting treatments while an imaging method 
20 
 
that quantified vascular properties would be valuable in assessing vascular- or Jak2-
targeted therapies. In the following chapter, two specific imaging techniques are 
discussed. 
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CHAPTER IV 
 
CANCER IMAGING 
 
Overview 
As with the treatments described previously in Chapter III, there are imaging 
techniques that are designed to be sensitive to particular aspects of a disease state such as 
cancer. Imaging has an important role in cancer therapy in that it offers a relatively non-
invasive method for tracking the response to certain therapies. In this work, two MRI 
based methods, dynamic contrast enhanced-MRI (DCE-MRI) and diffusion weighted-
MRI (DW-MRI), are used to look specifically at the cellular and vascular aspects of 
cancer. 
 
DCE-MRI 
One technique that has been shown to be sensitive to changes in physiological 
characteristics of tumor vasculature including perfusion, blood vessel permeability, blood 
volume, and the extravascular extracellular volume fraction, is DCE-MRI (1,2). This 
technique characterizes the pharmacokinetics of an injected contrast agent as it enters and 
exits a region or tissue of interest (ROI/TOI). Typical, MRI contrast agents are based on 
gadolinium (Gd) chelates, as discussed previously in Chapter II.  Recall that as the CA 
interacts with the surrounding tissue, the longitudinal relaxation time will shorten, 
leading to a signal intensity increase on a T1-weighted image. By acquiring T1-weighted 
images of the MRI signal over time, the kinetics of the CA can be modeled, and 
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biologically relevant parameters can be extracted that represent changes in, for example, 
blood flow, permeability, and tissue volume fractions.  For this type of quantification, 
three main components, which will be discussed in further detail below, are required: 1) a 
T1 map prior to the injection of the CA (discussed in Chapter II), 2) serial T1-weighted 
images acquired during the injection, and 3) the vascular or arterial input function 
(VIF/AIF).  
 
Each image acquisition represents one time point, and the resulting TIC from each 
voxel can be analyzed with a mathematical model.  Fig. IV-1 demonstrates an example 
time intensity curve (TIC) selected from a voxel within the tumor. Since the kinetics of 
the CA depend on the physiological characteristics of the tissue, pathological conditions 
such as cancer show distinct differences from that of normal tissue. This observation can 
be exploited in order to diagnose cancer and monitor treatment.   
 
 
Fig. IV-1.  An example of the change in concentration within the tissue of interest over 
time. The (.) represent actual data while the solid line represents the model fit to this 
data. 
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Dynamic Acquisition 
In order to observe the T1 changes induced by the injected CA, T1-weighted images 
must be acquired before, during, and after the injection. As with any MR imaging 
protocol, trade-offs exist between temporal resolution, spatial resolution, and signal to 
noise. In oncology applications, it is important to cover as much of the lesion volume as 
possible; in addition, the acquisition must be rapid enough to characterize the CA kinetics 
in a heterogeneous tumor region. Typical temporal resolutions can range from 1-30 
seconds, depending on the application. If modeling tumor CA kinetics on a voxel-by-
voxel basis to map tumor heterogeneity is required, then spatial resolution must be high 
enough to probe the details of the lesion. However, increasing the spatial resolution 
necessarily limits the temporal resolution and signal-to-noise of the acquired data.  Thus, 
the relative importance of temporal resolution, spatial resolution, and signal-to-noise 
(SNR) is dependent on the goals of the study; considerations for these trade-offs will be 
discussed in the following section. 
 
Vascular/Arterial Input Function 
In order to perform a quantitative analysis of DCE-MRI data, knowledge of the 
kinetics of the CA in the plasma blood (vascular/arterial input function or VIF/AIF
1
) is 
required. While this is not a unique problem to DCE-MRI, technical demands make 
accurate quantification of the VIF/AIF difficult. Typical characteristics of the VIF/AIF 
from a bolus injection include a rapid wash-in of high CA concentration (A), followed by 
 
1 In this work VIF and AIF are used interchangeably; however the two do have a subtle difference.  The VIF describes the time 
course of concentration of CA in the vasculature, whereas the AIF refers only to the arterial concentration. At early time points, the 
arterial and venous concentrations differ, but later the concentration equilibrates; hence, the changes in the blood pool examined in 
this work focus mainly on arterial concentrations but can be generalized in terms of a vascular input function. 
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a short-lived peak concentration value (B), and an exponentially decaying wash-out 
period (C) as shown in the VIF/AIF in Fig. VI-2.    
 
Capturing the peak is one of the most critical and most difficult tasks due to the need 
for rapid sampling (1-2 seconds) and high SNR. Several techniques for obtaining the 
VIF/AIF are discussed. The current “gold standard” for measuring the VIF/AIF is taking 
arterial blood samples during the imaging acquisition (3,4). Very accurate VIF/AIFs can 
be obtained with this method in that CA concentration can be determined directly from 
these samples. However, the invasive nature of this method is a substantial drawback. To 
characterize the rapid rise and wash-out of the CA in the blood, obtaining blood samples 
at a high enough temporal resolution is also very difficult. For preclinical studies with 
mice, the typical blood volume of a mouse is ~ 2 mL; thus, the number of blood samples 
that can be obtained is quite limited. 
 
Fig. IV-2.  An example of a typical vascular input function obtained from the left 
ventricle of the mouse. (A) illustrates the rapid rise during a bolus injection of contrast 
agent while (B) depicts the peak amplitude of measured contrast agent concentration 
and (C) shows the wash-out of the CA as it diffuses to the tissue. 
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Another method for estimating the VIF/AIF is derived from the image data itself. By 
strategically positioning the field of view to include a large vessel or left ventricle of the 
heart, the signal from the blood can be converted to describe the changing concentration 
of the CA during the injection. While this technique is certainly less invasive than blood 
sampling, it requires the presence of a blood pool in the field of view, which is not 
always conveniently located near the lesion of interest. Additionally, care must be taken 
to avoid partial volume or flow effects when measuring the VIF/AIF in this manner. As 
mentioned above, rapid scanning is required to capture the VIF/AIF peak (seen in Fig. 
IV-2) and this results in lower spatial resolution and/or lower SNR.  Also, in high 
concentrations, such as that seen during the first pass of the CA bolus, T2
*
 effects can 
diminish the measured MR signal in the image, providing an inaccurate estimation of the 
peak CA concentration in the blood. T2* decay occurs due to field inhomogeneities and 
by introducing a large bolus of CA, such inhomogeneities can dampen the signal from T1 
dramatically (5). Dosage and imaging parameters (TE, gradient spoiler amplitude, etc.) 
should be optimized to eliminate T2
*
 effects. An example of this effect is shown in Fig. 
IV-3.  
29 
 
 
If arterial input functions are measured from the left ventricle of a heart (in this case, 
from a mouse), dose optimization is critical. If the concentration is too high, as seen with 
a 0.3 mmol/kg injection of Gd-DTPA, the signal will be severely diminished but if the 
dose is too low, the signal-to-noise will not be enough to differentiate the signal from 
background noise.  Some sequences have been designed to measure both T1 and T2
*
 
relaxation during a dynamic scan such that the effect of T2
* 
can be quantified and 
corrected at the expense of temporal resolution (6).  
Alternatively, “reference region” (RR) approaches have been applied to DCE-MRI 
techniques if a large vessel or blood pool is not present in the field of view (7-9). 
Specifically, if a sample of tissue is well-characterized (i.e., muscle), the time course 
from that tissue can be used to calibrate the signal from the region of interest and the 
need for estimating the VIF/AIF is eliminated with this technique. The high temporal 
resolution required to accurately capture the VIF/AIF can now be used to increase spatial 
 
Fig. IV-3.  Example time courses using two different doses, 0.3 mmol Gd-DTPA/kg 
(a) and 0.025 mmol Gd-DTPA/kg (b). At high doses, T2* effects can diminish the 
apparent peak concentration while doses that are too low cannot be distinguished from 
the noise floor.  
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resolution, which improves the ability to probe tumor heterogeneity. Studies with a RR 
model have reported both good correlation with blood sampling analysis (10) as well as 
reasonable repeatability (11) and reproducibility (12). However, if the reference region 
shows much variability, or is poorly characterized, the accuracy of the approach suffers.   
Because of the difficulty associated with measuring the VIF/AIF, many studies have 
used a cohort of similar subjects to obtain a population average VIF/AIF (13,14). The 
population average VIF/AIF is then applied to other similar subjects in additional studies. 
An example of this approach is shown in Fig. IV-4, where five mice were imaged on 
separate days.  The group averaged, or population, VIF/AIF is displayed in black. 
 
If a population VIF/AIF is used, the temporal resolution required to capture the 
kinetics of the individual VIF/AIF can now be “traded” for addition spatial resolution 
and/or signal-to-noise for the region of interest since changes in tissue are much slower 
than changes in the blood.  Thus, during subsequent studies, spatial resolution can be 
 
Fig. IV-4.  Multiple arterial input functions measured from the left ventricle of 
five mice. The black line depicts the population average of this cohort of mice. 
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increased, and the population VIF/AIF can be used to drive the kinetic modeling. 
However, the obvious drawback to this technique is the inter- and intra-subject variability 
that may induce systematic errors in the pharmacokinetic parameters extracted from the 
models. When pursuing this technique, physical variation between subjects must be 
minimal, and DCE-MRI protocol set-ups must be identical to that used in obtaining the 
population-derived VIF/AIF; this method will be discussed in detail in subsequent 
chapters. 
 
Modeling 
Mathematical models are frequently employed to understand and quantify underlying 
physiology. Models for contrast agents have been developed that describe the 
introduction, distribution, and clearance of the agent within the body; specifically for 
DCE-MRI, extravasation of the CA in tissue can indicate physiologic parameters such as 
blood flow, vessel wall permeability, and tissue volume fractions of the tissue (1). The 
most commonly used model, developed by Kety in 1951, divides the body into two 
compartments: the blood/plasma space (denoted by Cp) and the tissue space (denoted by 
Ct) as shown in Fig. IV-5 (15).  
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Using the notation standardized for DCE-MRI by Tofts et al, in 1999, K
trans
 
represents the transfer constant from the plasma space to the tissue space (5). This 
transfer constant has different physiologic interpretations depending on factors such as 
permeability and blood flow for the tissue of interest. This process can be described in 
four ways: 1) flow limited (areas with high permeability); 2) permeability-vessel surface 
area (PS) limited (areas with low permeability); 3) mixed flow and PS; and 4) clearance. 
Under each of these conditions, the definition of the transfer constant K
trans
 changes. For 
example, in highly permeable areas, K
trans 
is governed by the flow (F) of the CA in the 
plasma fraction of the blood (1-hematocrit) and can be defined as K
trans
 = F∙ρ∙(1-Hct), 
where ρ is tissue density, and Hct is the hematocrit. Similarly, if permeability limits 
extravasation, K
trans
 is then defined as the product of vessel permeability and surface area 
for the given tissue (PS∙ρ). In the mixed case, Ktrans is defined as the extraction fraction, E 
(= 1-e
(-PS/F(1-Hct))
) times F∙ρ∙(1-Hct). For tumors, PS limited or mixed models most likely 
best describe CA extravasation from the characteristic leaky vasculature (1). Contrast 
agents of different molecular size can also force specific weighting on K
trans
. Smaller 
 
Fig. IV-5. Two compartment model showing one compartment representing the 
plasma space while the other compartment is the tissue space. The contrast agent 
leaves the plasma space at a rate represented by K
trans
 and returns by K
trans
/ve. 
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agents are more permeable so the predominant component affecting K
trans
 is flow while 
larger agents are slower to extravasate, allowing K
trans
 to reflect vessel permeability. An 
example of the use of a larger agent is presented below. 
If we assume that a homogeneous distribution of CA exists in both compartments and 
there exists no back flux to either compartment, then any of the above cases can be 
generalized into a linear, first order ordinary differential equation describing CA kinetics 
into the tissue 
)()()()( tC/vKtCKtC
dt
d
te
trans
p
trans
t
.   (IV-1) 
 This equation can then be solved using (for example) the Laplace Transform, resulting in 
t
0
ute/v
transK
p
trans
t dueuCKtC
))((
)()( .  (IV-2) 
It is important to note that the term (1-Hct) has been applied to the blood pool to indicate 
the portion of the blood, Cb(t), that is well-mixed with the CA; Cp(t) represents the [CA] 
in the plasma space (1-Hct)∙Cb(t); thereby, the K
trans
 interpretations above have been 
simplified.  
The aforementioned mathematical model neglects the fraction of tissue that may 
contain vascular space. Investigators have shown that in some tissues such as muscle, the 
fraction of vascular space (vp) is so small (~0.02) that it can be considered negligible (16-
18). However, some investigators argue that tumor tissue may contain a non-trivial 
fraction of vascular space due to angiogenesis. If vp is ignored for a tissue that contains 
significant vascular space, the pharmacokinetic modeling will overestimate K
trans
, leading 
to erroneous results. An illustration of this extension has been adapted by Daldrup et al, 
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shown in Fig. IV-6, and has been used by other investigators (19,20). 
 
 
An extension of the two-compartmental model has been formalized to improve 
accuracy in highly vascularized tissues such that the tissue space is composed of not only 
extravascular extracellular space but also a plasma space, described by: 
( )( )
( ) ( ) ( )
trans
e
t
K / v t utrans
t p p p
0
C t K C u e du v C t .  (IV-3) 
Now, Ct is not only composed of the concentration of CA in the extravascular 
extracellular space (Ce) x ve, but also an additional plasma component within the tissue 
(Cp x vp); i.e., Ct = ve∙Ce + vp∙Cp. (We note that the contrast agents used in this study are 
strictly extracellular, so there that the concentration in the intracellular space, vi, is zero.)  
In these forms, if Cp(t) is measured, K
trans
, ve, (and vp) can be determined using a 
nonlinear least squares fit to the collected data, Ct(t). This analysis can be done on a 
voxel-by-voxel basis in order to produce parametric maps. 
 
Fig. IV-6.  Two compartment model showing one compartment representing the 
plasma space while the other compartment is the tissue space. Now, however, the 
tissue space is comprised of both plasma and interstitial components. 
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Applications 
By employing both the standard and extended two compartmental model described 
above, quantitative measures of K
trans
 and ve can provide valuable information regarding 
the efficacy of anti-cancer drugs. For example, Checkley, et al examined both drug 
efficacy and dose-dependent response using DCE-MRI parameters as primary metrics 
(21). ZD6474 is a VEGF receptor 2 (KDR) tyrosine kinase inhibitor that prevents 
endothelial migration and proliferation (22,23). In this study, athymic mice were 
inoculated with PC-3 human prostate adenocarcinoma xenografts on the hind limb. After 
reaching approximately 1.0 cm
3
, the mice were divided into controls that received a 
vehicle treatment and mice that received a dose of ZD6474; this study was repeated for 
doses ranging from 12.5, 25, 50, and 100 mg/kg, administered in two doses at time 0 hr 
and 22 hours. DCE-MRI data was collected pre-treatment and 24 hours post-treatment. 
Data were acquired at 4.7T; a saturation recovery experiment with TR values ranging 
from 120, 500, 2000, and 10000 ms (TE = 16 ms) was used to calibrate signal to pre-
contrast T1. The dynamic acquisition employed a spin echo sequence with a TR/TE = 
120/10 ms, an acquisition matrix of 512 × 256 × 4 slices, resulting in a spatial resolution 
of 0.625 × 0.312 × 2 mm. At a temporal resolution of approximately 16 s, 5 baseline 
images were acquired, followed by a 0.01 mL/g dose of Gd-DTPA over a 3 s injection. 
Imaging continued for 11 more minutes for a total of 40 image sets. Relaxivity for Gd-
DTPA was measured using mouse blood samples dosed with known concentrations of 
Gd-DTPA and the VIF/AIF was obtained from another set of mice (physiologically 
identical) and fit to a bi-exponential decay. A reproducibility study was also done using 
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11 vehicle controls. It was found that there was no significant difference between K
trans
 (P 
= 0.4) and ve (P = 0.1) as measured on the same animal during two different imaging 
sessions.  No change in growth was reported during the 24 hours treatment study; 
however, a significant reduction in K
trans
 for doses ≥ 25 mg/kg and in ve for doses > 50 
mg/kg were identified. Chronic dose yielded significant volumetric difference at day 11. 
Since K
trans
 was not significantly different at 12.5 mg/kg and significant changes in K
trans
 
between doses were demonstrated, the authors suggest that K
trans
 is dose-dependent. This 
study illustrates the utility of DCE-MRI in anti-angiogenic treatment studies at early 
response time. 
As explained in the previous section, depending on the vascular environment, 
modeling can be flow-limited, permeability-limited, or mixed. The use of 
macromolecular rapid clearance blood flow agent that is larger and therefore crosses the 
endothelium more slowly can be used to control the weighting of flow and permeability 
on K
trans
. In Bradley et al (24), gadomelitol with a molecular weight of 6.47 kDa (as 
opposed to the frequently used Gd-DTPA, with a molecular weight of 0.5 kDa), was used 
to model components of the tissue curve that represented flow and permeability in order 
to explore the effects of two anti-angiogenic drugs, AZD 2171 and vandetanib. AZD 
2171 and vandetanib both inhibit VEGF receptor type 2 tyrosine kinases and have 
previously shown a drastic reduction in tumor blood flow and permeability (23,25). 
Nineteen male athymic AP rats were inoculated with SW620 colorectal adenocarcinoma 
tumor cells on the forelimb flank (dorsal to the heart). After 10 days, 8 rats were treated 
with AZD 2171 (3 mg/kg), 8 rats were treated with vandetinib (50 mg/kg), 3 were treated 
with vehicle controls. All rats were treated again after 22 hours and were imaged pre- and 
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23 hr post-treatment. One of the emphasized points of this study was the meticulous 
imaging protocol. Tumors were placed just above the heart in order to capture both the 
region of interest as well as the left ventricle of the heart to capture the VIF/AIF. Imaging 
was performed at 4.7T and a semi-keyhole technique (sampling only a portion of k-space) 
was incorporated to improve temporal resolution (26). Gadomelitol gel phantoms of 
various concentrations were also included in the field of view to calibrate signal intensity 
to agent concentration. The dynamic acquisition was done with a SPGR sequence with 
TR/TE = 13/9/2.3 s, α = 15⁰, FOV = 602, and the acquisition matrix = 128 × 96. With 
these parameters, a temporal resolution of 0.5 s/image was obtained; with this fine of a 
resolution, the rapid enhancing VIF/AIF in the left ventricle was adequately sampled for 
each subject. Baseline images were taken for 15 s, followed by a bolus injection of 0.045 
mmol/kg of CA over 2-3 s with 5 minutes of additional imaging. The VIF/AIF peaked at 
approximately 1.15 mM of CA for all animals. The extended two compartmental model 
(with vp term) was used, and the tissue curves were analyzed such that F/vT, vp, and PS∙ρ 
where F, vp, P,S, and ρ have been defined in the previous section and vt is the total 
volume of the image voxel. Animals that were treated with the angiogenic drug show 
significant changes in vascular related parameters, PS∙ρ (19.7 ± 9.5% and 28.9 ± 14.1%) 
and vp (31.2 ± 19.1% and 54.8 ± 21%) while no effect was seen in F/vT. This study 
explored the use of a larger molecular weight contrast agent to discern effects on 
permeability and blood flow on anti-angiogenic drugs. Furthermore, an imaging protocol 
was designed, optimized and strictly adhered to in order to help minimize parametric 
variability. 
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DW-MRI 
 
Introduction 
As mentioned previously, the majority of MRI applications use magnetic fields and 
radiofrequency energy to acquire signals from the hydrogen nuclei contained in tissue 
water. While the contrast in MRI is typically due to variations in the nuclei density and 
relaxation, the mobility or diffusion, of this water can also be probed to extract 
information about cellularity. 
 
Physical Basis 
Self-diffusion or Brownian motion is due to the microscopic random walk of water 
molecules (27).  In a system that is defined by small compartments, such as cells, that are 
separated by semipermeable barriers, such as cell membranes, the rate of this self 
diffusion, which is also described as the apparent diffusion coefficient (ADC), depends on 
the spatial relationship between these barriers (28-30). Hence, the cell membranes act to 
restrict the diffusion of water molecules.  
Techniques such as a pulsed-gradient spin-echo (PGSE) sequence have been designed 
to be sensitive to this diffusion and the effects of restrictions on water movements at 
spatial scales up to the order of several microns; this spatial scale is on the order of the 
diameter of a cell and therefore can be used as an estimate of cellularity. 
Consider a spin at a particular position x with gyromagnetic ratio , precessing in the 
transverse plane about magnetic field B in the z-direction (Bz).  At its current position, the 
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spin is labeled by magnetic field gradient, G, applied in the x-direction, and accumulating 
phase, , over time, ,  described by 
δxγGdtxGγφ 1x
δ
0
1x1 . (IV-4) 
 If a magnetic field gradient, equal in magnitude to the first, is applied in the opposite 
direction some time later, Δ, the spin will experience a different phase accumulation 
described by 
δxγGdtxGγφ 2x
δΔ
Δ
2x2 . (IV-5) 
If the spin undergoing these two pulses remains stationary (i.e., x1=x2), then there will be 
no net phase (φ2 - φ1 = 0); however, if the spin moves (x1 ≠ x2), then there is a net phase 
displacement. This phenomena is demonstrated in Fig. IV-7.  
 
 
Fig. IV-7. As the spins are labeled by the first magnetic field gradient, a spin may 
diffuse, accumulating some phase. As the second magnetic field gradient (equal in 
magnitude but opposite in direction), is applied, spins that have not moved will 
acquire no net phase displacement while spins that have diffused will not acquire a net 
phase displacement. 
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If we extend this model to a large number of spins which is assumed to have a Gaussian 
distribution of phase displacement, the total diffusion weighting imparted on the spins by 
both the imaging- and diffusion-sensitizing gradients, denoted as b-value or b,  can be 
described (details provided elsewhere (5)) as 
3
δ
ΔADCGGδγb ji
22
ij , (IV-6) 
where ADC is the apparent diffusion coefficient of the molecule in question. Based on 
Einstein‟s equation,  
2Dtr 2 ,  (IV-7)  
if the diffusivity (D) of free water at body temperature is ~ 2.5 µm
2
/ms, within an interval 
of approximately 35 ms (t), water will move ~ 13 µm ( <r
2
> ), which is approximately the 
size of a cell. Thus, by adjusting the timing of a DW-MRI sequence, an estimation of 
cellularity can be determined based on the presence of cellular membranes.  
  
Modeling 
By recalling the spin echo equation from a previous chapter, the signal depends on 
proton density, T1, and T2 relaxation. During a diffusion experiment, the signal will 
change due to diffusion as well and now the signal can be described as  
bADC2TE/T1TR/T
0 eee1SS )( , (IV-8) 
where b is given by (IV-6). If TR is set to a value greater than that of the T1 of the tissue 
of interest and TE is minimized to shorter than the T2 of the tissue of interest, then the 
signal will be dependent on diffusion 
bADC
0 eSS . (IV-9) 
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By changing the magnitude or duration of the diffusion gradients, thus changing the b-
values, and acquiring multiple image sets, the data can be exponentially fit to acquire 
ADC values on a voxel by voxel basis, as shown in Fig. IV-8. 
 
Applications 
Because of its high sensitivity, DW-MRI has also been used to monitor treatment 
response in a variety of anti-cancer therapies, including both cytotoxic and anti-
vascular/anti-angiogenic drugs (31-33). However, the specific changes in tissue that lead 
to these changes in ADC are not fully understood, and other processes can lead to 
increases or decreases in ADC.  Changes in active transport, blood flow or perfusion and 
bulk motion can potentially confound ADC measures as a surrogate for cell density (34). 
Additionally, tissue organization also contributes to the water movement. For example, 
an area that is densely packed with tumor cells will have a reduced ADC value due to the 
increase in cell membranes present, but if the an area with sparse tumor cells has 
 
Fig. IV-8. A mono-exponential fit to diffusion data acquired at three different b-
values. This fit returned a value of 0.0026 mm
2
/s as the ADC value of the sample. 
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increased extracellular matrix (ECM), ECM components, or  macrophage activity lending 
to an increase in extracellular space tortuosity, a reduced ADC value may also be reported 
(34).  As the cellular and extracellular environments change during the course of 
treatment, ADC has been used extensively to report areas of increasing necrosis and even 
malignancy grade (31,35). 
Correlations with ADC maps and tumor cellularity have been demonstrated (36-41). 
Subsequently, maps of ADC have also been used to examine treatment response in a 
variety of types of tumors, in both preclinical and clinical settings. In one study, DW-
MRI was used to predict treatment outcome for a high grade brain tumor model. After 
10-12 days after tumor inoculation, rats were imaged using a diffusion-weighted 
sequence to obtain an ADC map of multiple slices of the tumor. After several baseline 
scans were acquired, 13 animals were treated while 20 animals were not; all animals were 
imaged every two days following baseline scans for approximately 20 days. The results 
of this study found that diffusion measurements were significantly sensitive to therapy-
induced changes (42).   
In another study, DW-MRI was used to assess treatment efficacy of a vascular 
disrupting treatment regime. Seventeen male adult rats were implanted with two 
rhabdomyosarcoma tumor fragments on each flank. After the tumors reached 
approximately 2 cm
3
, 14 rats were placed a group receiving an intraperitoneal dose of 25 
mg/kg of combretastatin A4 phosphate (Oxigene, Watertown, MA), which is a vascular 
disrupting agent similar to those treatments described in Chapter III, while three rats were 
used as controls receiving saline injections. Rats were imaged 1 hour, 6 hours, and 2 days 
after treatment (or saline) administration, sacrificing three rats at each time point. 
43 
 
Anatomical and contrast enhanced images were acquired at 1.5T in addition to the DW-
MRI protocol. The DW-MRI protocol included an echo planar imaging scheme with the 
following parameters: TR/TE/NEX: 3300 ms/124 ms/4, acquisition matrix = 96 × 192 for 
a FOV = 81.3 mm × 130 mm (with 20 sections at a thickness = 0.2 mm with 0.2 mm 
gap), and b-values = 0, 50, 100, 150, 200, 250, 300, 500, 750, and 1000 s/mm
2
.  ADC 
maps were created using all b-values in addition to separate ADC maps to differentiate 
perfusion and diffusion effects; low b-values were used to create ADC maps that reflected 
perfusion while the high b-values created ADC maps that reflected water movement from 
diffusion. The results of this study demonstrate the transient change in ADC in response 
to treatment. Average ADC for the entire tumor showed an initial decrease immediately 
(1hr and 6hrs) post-treatment while at day 2, ADC increased significantly. Histology 
showed that this was due to the collapse of vasculature and subsequent crowding of 
endothelial cells into the extracellular space; at day 2, the high ADC reflects areas of 
developed necroses (43).  
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CHAPTER V 
 
OPTIMIZATION OF A MURINE VASCULAR INPUT FUNCTION MRI 
ACQUISITION PROTOCOL 
 
As discussed in chapter IV, the typical characteristics of the VIF from a bolus 
injection include a rapid wash-in of high CA concentration up to a sharp peak 
concentration and a bi-exponentially decaying wash-out period (see Figure IV-2). 
Capturing the first pass of the bolus is critical; previous literature suggests that if there is 
a 10% error in peak estimation, it will contribute to a 5-7% error in DCE-MRI parameters 
(1). However, it is extraordinarily difficult in small animals due to the need for high 
temporal as well as adequate spatial resolution.  
To circumvent issues associated with other VIF acquisition protocols, some 
investigators measure the VIF using the imaging data itself. While this method is 
noninvasive, strategically including a blood pool in the field of view (FOV) can limit the 
location of the region of interest (ROI).  Additionally, the spatial resolution must be high 
enough to minimize partial volume or flow effects, while the temporal resolution must be 
high enough to capture the peak of the VIF.  Because of these requirements, SNR, the 
number of slices, and spatial resolution over the tumor are typically compromised. 
Because of the difficulties in obtaining a high-quality VIF from every subject at every 
time point, some investigators have used a population-averaged VIF for data analysis.  
Typically, a cohort of patients or animals is used to obtain multiple individual VIFs, 
which are then averaged together to form a high-SNR population VIF (2-4). Then, the 
DCE-MRI treatment study is performed using a separate cohort, and the population 
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derived VIF is used for all subjects. Thus, the temporal resolution can be “traded” for 
higher spatial resolution and/or increased SNR, and the location of the imaging ROI 
becomes less important since a major vessel is not required in the FOV. This higher 
spatial resolution is particularly important when characterizing the heterogeneity of the 
tumor on a voxel by voxel basis. 
In order to arrive at an accurate, population-derived VIF, a cohort of mice must be 
used to obtain a number of individually measured VIFs. The following work describes 
optimizations to an MRI protocol in order to accurately obtain multiple individual VIF 
data from the left ventricle in a cohort of mice. 
 
Relaxivity 
First, the relaxivities of the contrast agents used in subsequent experiments were 
determined. Phantoms for Gd-DTPA and P846 were constructed using five tubes of 
saline containing concentrations of 0, 0.25, 0.75, 1.5, and 4.5 mM (2.3 mM for P846). 
The inversion recovery snapshot FLASH (Fast Low Angle SHot) gradient echo sequence 
(described in greater detail below) was used with the following parameters: TR/TE = 12 
s/2.12 ms, α = 15°, NEX = 2, acquisition matrix = 642, and FOV = (35 mm)2 with a slice 
thickness of 2 mm. Twenty-two images at linearly spaced inversion times ranging from 
10 ms to 10 s were collected. ROIs within each tube were fit to an inversion recovery 
equation in order to determine the R1 of each concentration. 
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Fig. VI-1 shows the plot of the respective R1 values for each vial concentration for each 
agent. Linear regression was performed on the data producing a slope that reflected the 
relaxivity for each agent at 7T of 4.72 mM
-1
s
-1
 for Gd-DTPA and 10.62 mM
-1
s
-1
 for P846. 
This experiment was also performed at 9.4T producing a relaxivity of 4.8 mM
-1
s
-1
 for Gd-
DTPA. 
  
Parametric Optimization 
Once the relaxivity was determined, a spoiled gradient echo sequence was optimized 
to maximize the SNR, temporal and spatial resolution at 7T. First, the flip angle was 
determined to maximize the difference between signal from the tumor (T1 ≈ 2.5 s) and 
signal from blood containing contrast agent (T1 ≈ 1.3 s) to provide the highest contrast 
between these tissues of interest in this study. The signal for each of these two regions is 
plot over a range of flip angles in Fig. V-2.  
 
Fig. V-1. Relaxivity fits for Gd-DTPA (a) and P846 (b). Each point represents the 
measured R1 value for one of the five vials containing various concentrations of 
contrast agent. The solid line illustrates the linear fit to the data to extract the 
relaxivity (slope). 
 
a
 
b
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With the flip angle optimized at 10°, the following parameters were used to image one 
slice containing the left ventricle and tumor tissue: TR/TE = 6/2.31 ms, NEX = 4, 
acquisition matrix = 64
2
, and FOV = (25 mm)
2
 with a slice thickness of 2 mm. The 
temporal resolution was approximately 1.5 s/image while the spatial resolution was 0.39 
× 0.39 × 2 mm
3
. Seventeen dummy scans were incorporated in order to ensure steady 
state was reached prior to the acquisition of relevant data, and spoilers were increased to 
3 G/cm to ensure no transverse magnetization remained. 
 
Localization Optimization 
In order to obtain the desired slice, positioning within the animal also had to be 
optimized. Since the left ventricle of the heart is relatively small (approximately the size 
of a pencil eraser), the slice had to reflect the maximum area of the left ventricle such that 
minimal respiratory and cardiac motion would be reflected in the VIF measurement.  
 
Fig. V-2. Simulation illustrating the change in signal intensity over flip angle for two 
tissues with different T1 values. The blue line represents signal from blood containing 
CA while the red line represents signal from the tumor tissue. The black line is the 
difference between the two which is maximized at a flip angle = 10°. 
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Fig. V-3 shows a series of scouts that were used to determine the ideal slice. Gated 
coronal and sagittal slices were gathered to plan the appropriate axial-oblique slice. If the 
slice is too close to the mitral valve, there is an increased likelihood of flow effects; 
however, if the slice is too close to the apex, myocardial wall contamination could skew 
the VIF measurement. 
 
Dose Optimization 
As mentioned earlier, in high concentrations, such as during the first pass of the 
contrast agent bolus, T2
*
 effects can significantly diminish the measured MR signal, 
providing an inaccurate estimation of the CA concentration in the blood. Dosage was also 
optimized to mitigate these T2
*
 effects. An example of this effect is shown in a previous 
Fig. IV-3. If the concentration is too high, as seen with 0.3 mmol/kg Gd-DTPA, SNR will 
be severely diminished but if the dose is too low, contrast to noise will not be enough to 
 
Fig. V-3. Illustration of scout images required to localize an oblique slice of the 
left ventricle of a mouse heart. The top row demonstrates gated coronal slices 
while the middle row shows gated sagittal slices. By planning from these two 
data sets, axial-oblique slices of the left ventricle can be obtained. 
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differentiate the signal from background noise. Optimum dose for each agent was found 
empirically to be 0.05 mmol/kg.  
 
T1 Mapping Optimization 
There are several techniques for obtaining T1 information, as discussed in Chapter II 
(5,6). As T1 of tissue is on the order of several seconds, measuring T1 can become a time 
consuming process, particularly when multiple slices of data are acquired. In order to 
optimize T1 mapping for the subsequent studies, several T1 methods were tested using 
Gd-DTPA doped vials of water that have T1 values that mimic a range a relevant 
biological tissue T1, as shown in Fig V-4.  
 
The methods which had the best estimation of these T1 were experimentally examined in 
vivo. Four T1 mapping techniques, shown in Table V-1, were compared to a single slice 
 
Fig. V-4.  Phantom vials used for T1 optimization;T1 values are denoted by the text 
within each vial.  
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(ss) inversion recovery snapshot FLASH (Fast Low Angle SHot) gradient echo sequence 
(for brevity, this technique will be referred to as „snapshot‟) as a gold standard. 
 
The snapshot sequence is a T1 mapping method that uses a non-selective adiabatic 
pulse which allows it to be more robust to B1 and B0 inhomogeneities that may skew T1 
measurements. For each inversion pulse, eight lines of k-space were acquired, making it 
faster than a typical inversion recovery experiment.  During the data fit, S0 was also a free 
parameter in order to account for incomplete longitudinal inversions. All compared 
TABLE V-1 
PERCENT ERROR OF COMPARED T1 METHODS. 
  
Percent Error 
Method 
Scan 
Length 
Vial 1  Vial 2  Vial 3  Vial 4  
(min) 
T1 = 0.99 
min 
T1 = 1.37 
min 
T1 = 2.57 
min 
T1 = 2.74 
min 
snapshot (ss)  
68 0 0 0 0 
17 TIs 
variable FA 
(ms)  4.5 31.45 43.527 35.167 37.851 
5 α with no B1 
variable FA 
(ms)  40.7 61.496 59.6 >50 >50 
5 α with B1 
FSEMS -IR 
(ms)  144 2.948 3.177 4.241 5.394 
18 TIs 
FSEMS -IR 
(ms)  56 0.456 0.168 0.008 1.525 
7 TIs 
SEMS -SR 
(ms)  42 25.774 34.361 20.981 36.607 
7 TRs 
FSEMS -SR 
(ms) 12 9.583 20.295 9.242 8.933 
 7 TRs 
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techniques were acquired at multiple slices as future studies would require this covering 
the entire tumor volume.  
The variable FA (flip angle) technique varies the flip angle, α, as shown in the 
gradient echo equation (Eqn. (II-9)), over a range from 10°-50° with a fixed TR and TE; 
the signal at five angles (10°, 20°, 30°, 40° , and 50°) were measured and the data was 
then fit to Eqn. (II-9)  to obtain T1. Since this technique relies heavily on the homogeneity 
of B1, B1 maps were collected to correct for heterogeneities as well (7). Data from a spin 
echo sequence (SEMS-SR) with seven TRs (200, 500, 800, 1000, 1300, 2000, and 4000 
ms) were also acquired and fit to Eqn. (II-8). In order to achieve the lowest scan time 
possible, fast spin echo inversion recovery (FSEMS-IR) and fast spin echo saturation 
recovery (FSEMS-SR) were incorporated into the comparison. Similar to snapshot, 
FSEMS experiments acquired multiple lines of k-space at a time in order to reduce 
acquisition time. FSEMS-IR administers a full inversion pulse and the signal was 
sampled at multiple inversion times (TI), as described in a previous chapter.  FSEMS-SR 
varied the TR with a fixed TE and was fit to Eqn. (II-8) to obtain T1 estimations. 
The method, total imaging time, and percent error for each vial tested are recorded in 
Table V-1. For the subsequent studies, a T1 mapping technique that took less than 60 
minutes was desired to minimize total in vivo imaging time. While variable FA methods 
are relatively fast, they can be very inaccurate at high field strengths due to 
inhomogeneities in the applied B1 field. FSEMS-IR seems to very accurate with an error 
(when compared to snapshot) less than 2%, but it takes 56 minutes to obtain this data. 
FSEMS-SR, at a 12 minute total imaging time was selected for a subsequent in vitro 
study; the results of this study are shown in Table V-2.  
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 Several FSEMS-SR protocols were tested and compared to the same phantom vials, 
using single slice (SS) snapshot as a gold standard. The number of TRs and NEXs were 
varied to obtain an accurate and fast T1 estimation. From this experiment, the highlighted 
protocols had less than a 2% error in multi-slice data and were tested in vivo. However, 
upon testing FSEMS-SR protocols in vivo, a gross overestimation of T1 values were 
found in both phantom and mouse muscle tissue, as shown in Fig. V-3. Water phantom T1 
TABLE V-2 
FURTHER IN VITRO EXPERIMENTS WITH POTENTIAL T1 ESTIMATION METHODS. 
 
Percent Error 
Method 
Scan 
Length 
Vial 1  Vial 2  Vial 3  Vial 4  
(min) 
T1 = 0.99 
min 
T1 = 1.37 
min 
T1 = 2.57 
min 
T1 = 2.74 
min 
FSEMS -SR 
(ms)  24.53 2.596 1.7 0.112 1.044 
9 TRs (NEX = 8) 
FSEMS -SR 
(ms)  16.35 2.524 0.942 0.064 0.86 
9 TRs (NEX = 6) 
FSEMS -SR 
(ms)  12.27 1.95 1.905 0.288 0.575 
9 TRs (NEX = 4) 
FSEMS -SR 
(ms)  22.19 2.692 1.604 0.078 1.132 
7 TRs (NEX = 8) 
FSEMS -SR 
(ms) 
20.48 2.678 1.629 0.016 0.887 
 6 TRs (NEX = 
8) 
FSEMS -SR 
(ms)  16.64 2.557 0.998 0.056 0.896 
7 TRs (NEX = 6) 
FSEMS -SR 
(ms)  11.09 2.034 1.883 0.266 0.696 
7 TRs (NEX = 4) 
FSEMS -SR 
(ms)  10.24 1.986 1.843 0.399 0.467 
6 TRs (NEX = 4) 
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values exceeded five seconds when spectroscopic results of water at 9.4T range from 3.4 
to 3.6 seconds, as similarly indicated by the snapshot data. This dramatic differences 
could be due to known magnetic transfer (MT) effects from off-resonance saturation seen 
in FSEMS protocols (8). 
 
To circumvent these issues, single slice snapshot was adapted to a multi-slice 
snapshot sequence, and testing showed less than a 5% difference in T1 from the single 
slice snapshot protocol.  For multi-slice snapshot, eight inversion times and a NEX = 4 
can estimate T1 values accurately with a total imaging time of 52 minutes. Once all of 
these optimizations were completed, individual VIFs were acquired and compared to a 
population-derived VIF described in the following chapter. 
 
 
 
Fig. V-5.  In vivo experiment between snapshot and FSEMS-SR reflecting a large 
overestimation in T1 measurements with FSEMS-SR. 
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CHAPTER VI 
 
 
A QUANTITATIVE COMPARISON OF THE INFLUENCE OF INDIVIDUAL- 
VERSUS POPULATION-DERIVED VASCULAR INPUT FUNCTIONS ON DCE-
MRI IN SMALL ANIMALS 
 
 
Introduction 
Currently, there are few studies that discuss the relative merits and accuracy of using 
the population VIF versus an individual VIF in small animals (1,2). Pickup, et al., 
obtained the VIF from the left ventricle of the imaging data in four mice. Temporal 
resolution for this study was approximately one image/s, but spatial resolution was 
severely restricted using only 16 phase-encode lines over a 2.5 cm field of view. 
Additionally, the injection was manually performed (1). More recently, another study by 
McGrath et al., compared the VIF in rats (using a manual injection) with frequently used 
VIF models and the population averaged VIF and reported the downstream effects on 
pharmacokinetic modeling parameters (2).  
The goal of this study is to assess the error in parameters extracted from DCE-MRI 
modeling of tumor tissue when using a VIF derived from a population average versus 
those extracted with an individually measured VIF in mice. These VIF measurements 
were obtained in a cohort of mice using two different contrast agents of varying 
molecular weight. The comparisons between pharmacokinetic parameters were 
performed on both an ROI and voxel-based analyses. Voxel analysis allows 
characterization of tumor heterogeneity while the ROI-analysis may be more typically 
used in a treatment response study. Additionally, performing voxel analysis allows for 
 60 
performing intra-animal comparisons that are not possible when just an ROI value is 
computed. Error and agreement between these methods are reported, and the subsequent 
power analysis and consequences for using either individual or population VIF in DCE-
MRI is discussed.   
  
Methods 
Tumor Model 
Murine 4T1 breast cancer cells were cultured in Dulbecco‟s modified Eagle‟s 
medium supplemented with 10% fetal bovine serum and 0.2% Gentamicin. Cells were 
incubated at 37
o
 C in a mixture of 5%/95% CO2/air. Cells growing at 80% confluence 
were harvested, and a single cell suspension containing 5 × 10
6
 cells suspended in 100 µL 
of medium was injected subcutaneously near the shoulder. Tumors were allowed to grow 
for six to nine days before imaging; tumor size ranged from 100 mm
3
 to 400 mm
3
 thereby 
producing a range of kinetic parameters.  
 
Animal Model 
Eleven female Balb/c mice (approximately 20 g, 8-10 weeks of age) were purchased 
from Charles River Laboratories (Wilmington, MA), housed in pathogen-free facilities 
and provided with rodent chow and tap
 
water ad libitum. A 26-gauge jugular catheter was 
surgically implanted to allow for delivery of the contrast agent. All animals were imaged 
twice: once using an injection of 120 μL of 0.05 mmol/kg gadopentetate dimeglumine, 
Gd-DTPA, (Magnevist, Wayne, NJ) (3) and once using an injection of 120 μL of 0.05 
mmol/kg P846 (Guerbet Research, Aulnay-sous-Bois, France) on a later day (4). During 
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all imaging procedures, the mice were anesthetized using a 2%/98% isoflurane/oxygen 
mixture. Temperature, respiratory rate, and electrocardiogram (ECG) signal were 
monitored throughout the entire experiment. All procedures in the experiment were 
reviewed and approved by our Institutional Animal Care and Use Committee.  
 
MRI Contrast Agents 
The two contrast agents used here were described in greater detail in Chapter II. 
Briefly, Gd-DTPA (3) and P846 (4-6) were used in this experiment. Relaxivities for Gd-
DTPA and P846 at 7T were found using the technique described in chapter V; the 
measured values of 4.71 s
-1
mM
-1
 and 10.62 s
-1
mM
-1
, respectively were used in 
subsequent data analyses. 
 
Data Acquisition 
MR imaging was performed using a Varian 7.0T Inova scanner equipped with a 
25 mm quadrature volume coil (both Varian, Inc. Palo Alto, CA). A respiratory- and 
ECG-gated gradient echo sequence was used to locate a 2 mm slice that both contained 
the tumor and cut across the short-axis of the left ventricle (LV) of the heart. Data for 
constructing a pre-contrast T1 map were obtained by an inversion recovery snapshot 
FLASH (Fast Low Angle SHot) gradient echo sequence with an adiabatic inversion pulse 
over nine inversion times (TI) ranging logarithmically from 200 – 6000 ms with TR\TE 
\α= 10000 ms\ 3.44 ms\15° and NEX = 4, FOV = 25 mm2, and matrix = 642 (7-9). The 
data were then fit to Eqn. (II-10).  
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The DCE-MRI protocol employed a T1-weighted, spoiled gradient echo sequence to 
obtain serial images at a temporal resolution of 1.536 seconds for 20 minutes with 
TR\TE\α = 6 ms\2.41 ms\10o, NEX = 4, and the same acquisition matrix and FOV as for 
the T1 map. A 120 µL bolus of 0.05 mmol/kg Gd-DTPA or P846 was delivered via a 
jugular catheter using an automated syringe pump (Harvard Apparatus, Holliston, MA, 
USA) at a rate of 2.4 mL/min after 100 baseline images were acquired.  
 
Data Analysis 
Data collected for the T1 map were fit using a nonlinear least squares method in 
Matlab 2008a (The Mathworks, Natick, MA, USA) to Eqn. (II-10). Once pre-contrast T1 
maps were calculated for the interrogated slice, regions of interest were drawn to include 
the entire left ventricle of the mouse. Each voxel was then converted to an R1 (= 1/T1) 
time course by the method of Landis, et al. (10) 
)(
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where R1, TR, TE, T2
*
 and α are described previously, S(t) is the signal intensity time 
course, and 
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where Sss is the steady state averaged signal intensity before contrast agent administration 
(pre-CA). At a short TE, T2
*
 contribution to the signal was assumed to be neglible. Using 
the R1 time course for the LV, the concentration of contrast agent in the plasma, Cp, was 
then determined using the fast exchange limit (FXL) assumption 
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10p11 RChct1rR )( ,  (IV-3) 
where r1 is the relaxivity for Gd-DTPA and P846, (values reported in Chapter V), hct is 
the hematocrit of a mouse (h = 0.45 was used in this study based on literature values (11)) 
and R10 is the pre-contrast R1 value. 
Due to potential flow and motion artifacts, a simple filter was employed to examine 
every voxel within the LV blood pool for specific characteristics; in particular, voxels 
were included in the VIF calculation if the SNR ≥ 30 at all time points and if the peak 
concentration was ≥ 0.15 mM, based on literature values (1). Each voxel returned was 
also visually inspected for appropriate wash-out activity to prevent potential myocardial 
wall contamination. An ROI in the left ventricle was drawn and all voxel time courses 
were graphically displayed. If the time course had an elongated wash-out  indicative of 
slower clearance (characteristic of tissue curves), it was excluded from analysis (typically 
only 2-3 voxels per animal). These appropriate voxels were then averaged together to 
represent the individual VIF for that animal. Once the individual VIFs were collected (N  
= 11 for Gd-DTPA and N = 9 for P846), they were aligned to the same initial uptake 
time. Briefly, the peaks (maximum value) of the individual VIFs were used to align the 
data to form the population VIF. Alignment typically varied 1-3 time points and 
interpolation (if needed) was either added to the baseline acquisition or at the tail end of 
the wash-out period. For each animal, an individual VIF (VIFind) and a population VIF 
(VIFpop), which was determined by taking the mean of the individual VIFs (excluding its 
own individual VIF), were used to fit that animal‟s ROI signal curves to both the standard 
and extended model represented in Eqs. Eqn. (IV-2) and Eqn. (IV-3) to extract K
trans
, ve, 
and vp.   
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Statistical Analysis 
By fitting the tissue signals to the standard (ST) and extended (EX) models with both 
VIFind and VIFpop, two sets of five parameters were produced: 1) using VIFind to obtain 
K
trans,ind
 (ST), ve,ind (ST), K
trans,ind 
(EX), ve,ind (EX), and vp,ind (EX); and 2) using VIFpop:to 
obtain K
trans,pop
 (ST), ve,pop (ST), K
trans,pop 
(EX), ve,pop (EX), and vp,pop (EX). Each parameter 
was paired for comparison (e.g., K
trans,ind
 (ST) and K
trans,pop
 (ST)); these “parametric pairs” 
were compared on two levels.  
First, an ROI was drawn around the tumor for each animal. The signal from the ROI 
was averaged to produce one R1 time course, which was then analyzed by both the 
standard and extended models. The absolute agreements between the resulting parametric 
pairs were then assessed using the concordance correlation coefficient (CCC) (12). 
Specifically, the CCC evaluates the degree to which these pairs fall on the line of unity 
when they are plotted against each other. Like the more common Pearson correlation 
coefficient, a perfect correlation of the pairs produce a CCC value of 1, while completely 
independent pairs produce a CCC equal to 0.  The Pearson correlation coefficient, was 
also calculated. In addition to the correlation indices, each parametric pair was analyzed 
using linear regression. We also performed a power analysis on each set of parameters to 
determine how many more samples are likely needed to detect 50% increase/decrease in 
the means with 80% power if the population VIF was used. This calculation is based on a 
two sample t-test. To account for the variability of the estimated standard deviation, we 
used a bootstrap sampling technique and reported the median sample sizes. 
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The second level of comparison was based on individual voxel data for each animal. 
Voxels within the whole tumor ROIs were fit individually to produce two sets of five 
parametric maps for all animals (as described above). To ensure that only properly fit 
data continued on for further comparison, voxel fits were filtered using a simple r
2
 filter 
(r
2 
> 0.6) for the VIFind data; additionally voxel data were filtered to ensure the resulting 
parameters fell within a physiologically relevant parametric range (0 < K
trans
 < 1 min
-1
, 0 
< ve < 1, and 0 < vp < 1). Voxels that could be fit using the VIFind but not the VIFpop were 
tabulated and reported in Table VI-7. For each animal, the CCC and Pearson correlation 
coefficient were determined on a voxel by voxel basis between the parametric pairs 
described previously; additionally these paired data were compared using linear 
regression. 
 
Modeling and Temporal Resolution Analysis 
Both raw VIFind and VIFpop data were fit to a bi-exponential decay model (13). 
Kinetic parameters produced using the fitted VIFind and fitted VIFpop data were compared 
using statistics similar to those described above in order to assess the accuracy of using a 
fitted VIFpop versus using a fitted VIFind. Additionally, ROI signal data were 
downsampled by selecting every 20
th
 point (simulating a temporal resolution of 
approximately 30 seconds) in order to simulate a realistic clinical acquisition with a 
reduced temporal resolution. Data were then interpolated using a linear interpolation 
scheme in Matlab (the „interp1‟ function) and fit to extract kinetic parameters using the 
VIFind and VIFpop as an input to the model. Kinetic parameters were compared with 
similar statistics as described above. 
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Results 
Using a standard injection protocol, the resulting population averaged VIF for both 
Gd-DTPA (n=11) and P846 (n=9) are presented in Fig. VI-1 (a) and (b) (black line); the 
grey lines represent one standard deviation from each population VIF. Fig. VI-1 (c) 
illustrates two VIFind from two separate mice using Gd-DTPA (blue dashed and red lines) 
compared to the VIFpop (black solid line).  
Note that while the red VIFind seems to fall along the VIFpop, the VIFind indicated by the 
blue dashed line has a slightly different wash-out period. Since P846 is a larger contrast 
agent, the P846 VIF has a longer wash-out period than those obtained using Gd-DTPA. 
The peak values for both agents were very similar across all subjects, yielding a standard 
deviation of approximately 15% while the wash-out was different for both Gd-DTPA and 
P846 with a standard deviation of 32% and 25%, respectively. 
 
 
 
 
Fig.VI-1.  Population derived VIFs using Gd-DTPA (N = 11) (a) and P846 (N = 9) 
(b). P846 had a longer wash-out period than Gd-DTPA due to its larger size. Both Gd-
DTPA and P846 have a relatively small standard deviation at the peak (13% and 15%, 
respectively). However, both have a larger standard deviation at ~5-10 minutes during 
wash-out equal to 32% and 25%, respectively. Panel (c) illustrates two example VIFind 
(blue dashed and red solid lines) compared to the VIFpop (solid black line). 
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ROI Analysis 
The first set of analyses examined the ROI averaged signal time course from the 
tumor of each mouse. Each averaged time course was then fit to Eqn. (IV-2) and Eqn. 
(IV-3) to extract the pharmacokinetic parameters. By modeling each time-intensity 
course using both the VIFind and VIFpop, two sets of five parameters (K
trans
(ST), ve(ST), 
K
trans
 (EX), ve (EX), and vp (EX)) were produced and the subsequent parametric pairs (i.e., 
K
trans,ind
(ST) and K
trans,pop
(ST)) were compared. Fig. VI-2 shows the results of this study 
for Gd-DTPA (a) and P846 (b).  
 
Upon visual inspection, these parameters appear to fall close to the line of identity for 
both agents; also in both agents, the parametric pairs for ve(ST) and ve(EX) tend to deviate 
from unity more than K
trans
(ST), K
trans
(EX), and vp(EX). The CCC, reported in Table VI-1, 
represents a quantitative measure of parameter proximity to the line of unity.  
 
Fig.VI-2 Parametric plots for both Gd-DTPA (a) and P846 (b) resulting from the ROI 
analysis. Each parameter is designated by the colored marker (for each animal) while 
the solid black line indicates the line of identity.  
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The CCC values for K
trans
 (both ST and EX) are > 0.90 for Gd-DTPA and > 0.85 for P846 
indicating a strong correlation between the pairs. However, the CCC values for ve (both 
ST and EX) are lower for both contrast agents (0.79 to 0.83 for Gd-DTPA and P846, 
respectively). Interestingly, while both the CCC for K
trans
 and ve were similar between the 
contrast agents, vp (EX) was very different.  The vp (EX) values estimated using Gd-
DTPA had a stronger correlation than the P846 data. In addition to the CCC, the Pearson 
correlation coefficients show a strong significant linear relationship between each paired 
TABLE VI-2 
POPULATION CHANGES RESULTING FROM THE ROI-BASED COMPARISON. 
 Δ%  in Population Size 
 Gd-DTPA P846 
K
trans
 (ST) 35 19 
ve (ST) -14 100 
K
trans
 (EX) 16 11 
ve (EX) -16 100 
vp (EX) 58 57 
 
TABLE VI-1 
RESULTS FROM THE ROI-BASED COMPARISON. 
 
CCC (95% CI) Pearson Intercept Slope 
Gd- 
DTPA 
P846 
Gd-
DTPA 
P846 
Gd-
DTPA 
P846 
Gd-
DTPA 
P846 
K
trans
 
(ST) 
0.93 
(0.81,0.98) 
0.93 
(0.73,0.98) 0.95 0.95 -0.02 0.00 1.20 1.10 
ve 
(ST) 
0.82 
(0.48,0.95) 
0.84 
(0.62,0.94) 0.83 0.94 0.08 -0.08 0.74 1.48 
K
trans
 
(EX) 
0.96 
(0.85,0.99) 
0.85 
(0.47,0.96) 0.96 0.85 -0.01 0.01 1.06 0.82 
ve 
(EX) 
0.80 
(0.42,0.94) 
0.82 
(0.58,0.93) 0.81 0.92 0.09 -0.07 0.69 1.45 
vp 
(EX) 
0.88 
(0.76,0.97) 
0.45 
(0.02,0.74) 0.98 0.73 0.00 0.00 1.54 1.61 
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set of parameters (ranging from 0.80 to 0.97). The results of the linear regression analysis 
agrees with the interpretation of the CCC in that K
trans
 (both ST and EX) have slopes close 
to 1.0 while ve and vp deviate from 1.0 by 30-40%.  
Table VI-2 conveys the change in the number of animals required to achieve the same 
power when using the VIFpop versus the VIFind. Relatively small increases in the number 
of animals are required for K
trans
 (ST) and K
trans
 (EX) using Gd-DTPA (35% and 19%, 
respectively),  K
trans
 (ST) and K
trans
 (EX) using P846 (11% and 16%, respectively). A 
smaller number of animals is required for ve measurements using Gd-DTPA (-14% for ve 
(ST) and -16% for ve (EX)) but require double the sample size using P846 (100% for both 
ve (ST) and ve (EX)). To achieve the same power for vp measurements, the sample size 
must be increased by half the number of initial subjects (58% and 57% for Gd-DTPA and 
P846, respectively).  
 
Voxel Analysis 
As described above, voxels for each animal were fit to Eqn. (IV-2) and Eqn. (IV-3) to 
yield paired parametric maps using both the VIFind and VIFpop. An example mouse is 
shown in Fig. VI-3.  
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Panels (a) - (c) demonstrate the parametric maps from the extended model 
overlaid on a (gated) T1-weighted anatomical image obtained using the VIFind during 
modeling, while panels (d) - (f) depict parametric maps obtained using the VIFpop. When 
 
Fig.VI-3.  Parametric maps determined using Eqn. (IV-3) overlaid on a (gated) T1-
weighted anatomical image for one mouse. Panels a-c depict the parametric maps 
using the VIFind while d-f show the maps resulting from using the VIFpop. Each 
parameter for each voxel is plotted with respect to its pair in g-i where the solid black 
line indicates the line of unity. Each data point has a set of dotted vertical red and 
horizontal blue lines that represent the 95% CI for the respective axes. A Bland-
Altman plot is presented in j-l for each parameter. The x-axis represents the average 
parametric value between those obtained using the VIFind and VIFpop while the y-axis 
is the percent difference between VIFind and VIFpop parametric estimations with 
respect to the VIFind parameter. The solid black line is the mean difference while the 
dotted red lines represent ± 2*standard deviation. The maps are very similar, 
particularly for K
trans
. However, overestimations in ve and vp are evident using the 
VIFpop versus the VIFind. The arrows in panels b and e emphasize the areas within the 
maps where ve found using VIFpop is overestimated relative to ve found using VIFind.  
In panels c and f, the overestimations are also noted for the vp parameter as well. 
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plotted against each other, as in panels (g) – (i) the voxel level data are linearly related 
(black line represents unity). Panels (j) – (l) illustrate Bland-Altman plots for each kinetic 
parameter with the x-axis representing the average parametric value between those 
obtained using the VIFind and VIFpop while the y-axis is the percent difference between 
VIFind and VIFpop parametric estimations with respect to the VIFind parameter. The solid 
black line is the mean difference while the dotted red lines represent ± 2×standard 
deviation. The slopes of the fit lines for K
trans
 pairs for the subject shown in Fig. VI-3 
differ from unity by 5-7% while the slopes of the fit lines for ve and vp deviate from the 
identity line by as much as 24-31%. Upon closer inspection of the maps of this particular 
mouse, the overestimation of ve and vp by the VIFpop (panels (e) and (f)) compared to their 
respective pairs (b and c) are shown by the arrows in panels (b), (c), (e), and (f). The 
differences between these estimations are quantified in panels (j) – (l). For this animal, 
confidence intervals (CI), shown as the vertical red and horizontal blue dotted lines for 
K
trans
 are very tight (g) while CI boundaries for ve tend to be tighter for lower values and 
increase as the value of ve increases (h). CI values for vp are quite large but are similar for 
both the VIFind and VIFpop (i).  
The CCC was computed for each animal for each parameter and results are presented 
in Fig. VI-4. Panels (a) – (e) in Fig. VI-4 display the plots of the CCC (x axis) for each 
animal (y axis) with the solid lines showing the 95% CI boundaries for each value while 
the number on the far right is the nominal CCC. 
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Fig.VI-4.  Panels a-e show the CCC plots for the respective kinetic parameter in the 
voxel based analysis found using Gd-DTPA; the P846 data is shown in panels f-j. 
Each plot displays the CCC values (y-axis) and 95% CI for voxels obtained from each 
animal (x-axis). The CCC values are listed in the column on the right side of the plot.  
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While the voxel-based analysis echoes the results of the ROI-based analysis, the 
difference between the parameter pairs is magnified for some animals. K
trans
 (both ST and 
EX) still reflects very high correlation with unity (panels (a) and (c)) with the exception 
of one mouse in the ST analysis and two mice in the EX analysis that used Gd-DTPA, that 
yielded a CCC > 0.90.  For P846, seven mice had CCC > 0.75 for K
trans
 (ST) (panel (f)). 
K
trans
 correlation for P846 is reduced in the extended model, yielding only five mice with 
CCC > 0.85. Three mice using Gd-DTPA had CCC < 0.70 for ve (both ST and EX), 
(panels (b) and (d)). For mice that were imaged using P846, eight had CCC > 0.70 for ve 
(panels (g) and (i)); again, modeling with the standard model provided higher correlations 
than the extended model for P846 data. Additionally, vp had nine mice with CCCs higher 
than 0.75 for Gd-DTPA data while only four had CCC > 0.75 using P846. Additional 
quantitative results from the voxel-by-voxel study are shown in Tables VI 3-6.  
    
      
 
TABLE VI-3 
VOXEL-BASED RESULTS FOR GD-DTPA DATA USING ST MODEL. 
Mouse 
Pearson Corr. 
Coefficient 
Slope Intercept 
K
trans 
(ST) 
ve 
(ST) 
K
trans 
(ST) 
ve 
(ST) 
K
trans 
(ST) 
ve 
(ST) 
1 1.000 0.992 0.927 0.796 -0.006 0.005 
2 0.999 0.996 1.090 1.340 0.010 0.005 
3 0.998 0.882 0.983 0.457 -0.011 0.084 
4 0.998 0.998 1.441 1.011 -0.031 0.017 
5 0.999 1.000 1.144 0.957 -0.008 0.008 
6 0.999 0.981 0.826 0.975 -0.011 0.023 
7 1.000 1.000 0.921 0.836 -0.002 0.008 
8 0.999 1.000 1.011 0.695 -0.004 0.001 
9 0.999 0.989 0.998 0.829 -0.011 0.033 
10 0.998 0.888 1.146 1.631 0.007 0.081 
11 0.993 0.975 1.047 1.565 0.011 0.037 
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Tables VI-3 and VI-4 show the Pearson correlation coefficient and linear regression 
results for Gd-DTPA for the standard and extended models, respectively. Tables VI-5 and 
VI-6 present results for P846 using the standard and extended models, respectively.  
  
 
 
 
The Pearson correlation coefficients reflect a high degree of linearity between parameter 
pairs in both Gd-DTPA and P846 data.  
TABLE VI-4 
VOXEL-BASED RESULTS FOR GD-DTPA DATA USING EX MODEL. 
Mouse 
Pearson Corr. 
Coefficient 
Slope Intercept 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
1 0.998 0.993 0.978 0.922 0.793 1.129 -0.010 0.004 0.001 
2 0.991 0.992 0.888 0.968 1.319 1.638 0.021 0.001 0.001 
3 0.997 0.924 0.976 0.909 0.488 0.957 -0.003 0.065 0.002 
4 0.998 0.998 0.949 1.248 0.939 1.725 -0.001 0.004 0.008 
5 0.997 1.000 0.991 1.072 0.956 1.371 -0.003 0.005 0.001 
6 0.986 0.980 0.868 0.784 0.958 1.401 -0.006 0.018 0.003 
7 1.000 0.999 0.990 0.921 0.833 0.979 -0.002 0.009 0.002 
8 0.987 0.999 0.999 0.890 0.647 2.186 -0.001 0.006 0.000 
9 0.998 0.987 0.881 1.027 0.826 0.953 -0.015 0.029 0.003 
10 0.995 0.863 0.957 1.096 1.609 1.454 0.009 0.106 0.002 
11 0.989 0.973 0.965 1.005 1.613 1.725 0.014 0.027 0.003 
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For Gd-DTPA data, the slopes for K
trans
 are close to 1.0 while ve and vp tend to deviate, 
thus indicating a lower correlation with unity.  
 
Comparing the two contrast agents, it appears that while both show high degrees of 
linearity, the average difference between the slopes of the fit line for K
trans
 data and the 
line of unity is greater for P846 relative to Gd-DTPA. Both Gd-DTPA and P846 data 
yield similar differences for ve, while vp has a much higher average difference between fit 
TABLE VI-6 
VOXEL-BASED RESULTS FOR P846 DATA USING EX MODEL. 
Mouse 
Pearson Corr. 
Coefficient 
Slope Intercept 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
K
trans 
(EX) 
ve 
(EX) 
vp 
(EX) 
1 0.982 0.846 0.987 1.469 0.597 0.869 -0.005 0.058 0.001 
2 0.989 0.997 0.983 0.925 1.251 1.313 0.010 0.013 0.004 
3 0.995 0.994 0.983 1.301 1.010 1.735 -0.011 0.002 0.002 
4 0.993 0.998 0.989 1.217 0.734 1.612 -0.023 0.004 0.003 
5 0.993 0.976 0.921 2.056 0.695 0.918 -0.029 0.047 0.004 
6 0.904 0.975 0.789 0.484 1.214 3.318 0.037 0.032 0.008 
7 0.993 0.993 0.990 1.028 1.328 1.784 0.007 0.006 0.002 
8 0.935 0.739 0.940 0.343 0.828 2.824 0.013 0.069 0.005 
9 0.960 0.986 0.935 0.301 0.517 1.824 0.007 0.002 0.002 
 
TABLE VI-5 
VOXEL-BASED RESULTS FOR P846 DATA USING ST MODEL. 
Mouse 
Pearson Corr. 
Coefficient 
Slope Intercept 
K
trans 
(ST) 
ve (ST) 
K
trans 
(ST) 
ve 
(ST) 
K
trans 
(ST) 
ve 
(ST) 
1 1.000 0.922 1.211 0.745 -0.002 1.211 
2 0.997 0.996 0.951 1.244 0.009 0.951 
3 0.999 1.000 1.232 1.038 -0.005 1.232 
4 0.998 0.999 1.327 0.750 -0.018 1.327 
5 0.998 0.972 1.865 0.770 -0.024 1.865 
6 0.990 0.999 0.811 1.309 0.025 0.811 
7 1.000 0.987 1.091 1.356 0.006 1.091 
8 0.997 0.964 0.597 0.903 0.005 0.597 
9 1.000 0.996 0.451 0.528 0.001 0.451 
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and unity lines. For both agents, the slope/intercept data reiterate the CCC findings seen 
in Fig. VI-4. 
 
Modeling and Temporal Resolution Analysis 
Upon fitting both the VIFind and VIFpop, absolute kinetic parameter values changed 
with respect to that of the raw data analysis, as shown in Table VI-7 for Gd-DTPA data; 
however, no significant difference was found in the statistical comparison between these 
absolute values produced.  
 
Additionally, comparing the parameters using the fitted VIFind and the fitted VIFpop 
shared similar statistics to comparing values produced using the raw VIFind and the raw 
VIFpop data, as indicated in Table VI-8. 
TABLE VI-7 
ABSOLUTE PARAMETER VALUES PRODUCED FROM RAW AND FIT VIF DATA. 
Mouse 
K
trans
 (ST) (min
-1
)         
from VIFind  
ve (ST)           
from VIFind 
 raw fit  raw fit 
1 0.128 0.131 0.374 0.373 
2 0.053 0.055 0.174 0.172 
3 0.064 0.065 0.483 0.468 
4 0.293 0.224 0.668 0.574 
5 0.128 0.128 0.326 0.327 
6 0.224 0.224 0.322 0.325 
7 0.280 0.286 0.745 0.740 
8 0.047 0.046 0.068 0.069 
9 0.117 0.122 0.374 0.369 
10 0.102 0.104 0.314 0.313 
11 0.025 0.026 0.168 0.165 
p-value 0.904 0.897 
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 The parameters resulting from the bi-exponential decay analysis resulted in the following 
parameters for the population VIF data: for Gd-DTPA, a1 = 0.0516 kg/L, m1 = 0.0450 
sec
-1
, a2 = 0.0820 kg/L, and m2 = 1.3045 sec
-1
; for P846, a1 = 0.0602 kg/L, m1 = 0.0452 
sec
-1
, a2 = 0.0516 kg/L, and m2 = 0.4920 sec
-1
. 
Parameters determined using the original sampled (1.5 sec) tissue signal and the 
parameters obtained by downsampling (ds) the data (30 sec) displayed an insignificant 
difference in absolute parametric values. Table VI-9 shows absolute K
trans
 (ST) and ve 
(ST) for all animals derived using the VIFind and both raw and downsampled data. A two 
tailed t-test showed that there were no statistical significances between these parameters; 
while not shown here, no statistical differences between using the raw or downsampled 
data were found in the EX model data or VIFpop data. 
TABLE VI-8 
STATISTICAL COMPARISON PARAMETERS PRODUCED BY RAW AND FIT VIF . 
 
Pearson Intercept Slope CCC 
Gd-
DTPA 
(raw) 
Gd-
DTPA 
(fit) 
Gd-
DTPA 
(raw) 
Gd-
DTPA 
(fit) 
Gd-
DTPA 
(raw) 
Gd-
DTPA 
(fit) 
Gd-
DTPA 
(raw) 
Gd-
DTPA 
(fit) 
K
trans
 
(ST) 
0.96 0.96 -0.02 -0.02 1.17 1.16 0.93 0.96 
ve    
(ST) 
0.91 0.91 0.07 0.07 0.81 0.81 0.82 0.85 
K
trans
 
(EX) 
0.96 0.96 -0.01 -0.01 1.04 1.11 0.96 0.97 
ve 
(EX) 
0.90 0.90 0.08 0.07 0.78 0.80 0.80 0.83 
vp 
(EX) 
0.98 0.98 0.00 0.00 1.52 0.99 0.88 0.69 
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The effect of using the population vs. the individual VIF to fit the data still follows a 
similar correlation trends as presented for the ROI analysis using the original temporal 
resolution. Statistical analysis showed that there was no significant difference between 
parameters found using the VIFind on the downsampled data versus the VIFpop on the 
downsampled data, shown in Table VI-10.  
TABLE VI-9 
ABSOLUTE PARAMETER VALUES PRODUCED FROM RAW AND DOWNSAMPLED VIF DATA . 
Mouse 
K
trans
 (ST) (min
-1
)    
from VIFind  
ve (ST) from VIFind 
raw ds raw ds 
1 0.128 0.166 0.374 0.354 
2 0.053 0.053 0.174 0.145 
3 0.064 0.091 0.483 0.634 
4 0.393 0.377 0.668 0.651 
5 0.128 0.162 0.326 0.308 
6 0.224 0.193 0.322 0.290 
7 0.280 0.303 0.745 0.710 
8 0.047 0.057 0.068 0.096 
9 0.117 0.120 0.374 0.365 
10 0.102 0.132 0.314 0.192 
11 0.025 0.044 0.168 0.185 
p-value 0.792 0.933 
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Discussion 
Measuring the vascular input function is one of the more challenging aspects of DCE-
MRI measurement and quantification, particularly in small animals. In Pickup, et al., 
only four mice were used in the study, and spatial resolution was sacrificed in order to 
obtain an adequate temporal resolution for VIF acquisition (1). A very comprehensive 
study by McGrath et al., compared the VIF in rats with frequently used VIF models and 
the population averaged VIF and reported the downstream effects on pharmacokinetic 
modeling parameters (2). To the best of our knowledge, no study has extensively 
examined the VIF in mice and the effects on pharmacokinetic modeling parameters. 
Additionally, this study has eliminated injection variability in that an automated syringe 
pump was used with identical settings for all animals.  
The temporal resolution requirements for measuring an accurate VIF typically are not 
compatible with the spatial resolution requirements of imaging a large heterogeneous 
TABLE VI-10 
STATISTICAL COMPARISON PARAMETERS PRODUCED BY RAW  
AND DOWNSAMPLED TISSUE CURVES USING VIFIND AND VIFPOP. 
  
Pearson 
  
Intercept 
  
Slope CCC  
 
Gd-
DTPA 
Gd-
DTPA     
(ds) 
Gd-
DTPA 
Gd-
DTPA 
(ds) 
Gd-
DTPA 
Gd-
DTPA 
(ds) 
Gd-
DTPA 
Gd-
DTPA     
(ds) 
K
trans
 
(ST) 
0.95 0.96 -0.02 -0.02 1.20 1.17 0.93 0.94 
ve 
(ST) 
0.83 0.89 0.08 0.08 0.74 0.69 0.82 0.85 
K
trans
 
(EX) 
0.96 0.96 -0.01 -0.02 1.06 1.13 0.96 0.95 
ve 
(EX) 
0.81 0.84 0.09 0.13 0.69 0.55 0.8 0.75 
vp 
(EX) 
0.98 0.97 0.00 0.00 1.54 1.00 0.88 0.95 
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tumor. In order to alleviate these technical demands, the use of a population VIF has been 
proposed, and this work has focused on assessing the feasibility and resultant error when 
using a population VIF instead of acquiring individual VIFs in mice. In order to construct 
an accurate population VIF, a consistent injection protocol must be established. The rapid 
injection protocol in this study was used for a two main reasons. Firstly, the shorter 
injection time has been shown to more closely relate K
trans
 to the initial uptake of the 
contrast agent within a given voxel as well as more closely relate ve to the accumulation 
of the agent extravascularly using this specific model (14). Additionally, a rapid injection 
protocol yields a rapidly rising, short-lived peak concentration which is typically the most 
difficult to capture and characterize; thus, the “worst-case” VIF was used in this work to 
compare the downstream effects on the kinetic parameters. We would anticipate the 
kinetic parameter comparison using a longer, slower injection protocol to be similar. 
Other injection protocols can be found in the literature (15,16)  
Care was also taken to minimize the error associated with a given VIF. A low dose of 
Gd-DTPA (0.05 mmol/kg) was used to reduce T2
*
 effects. Additionally, gated scout 
images allowed placement in the left ventricle such that: 1) the number of voxels in the 
center of chamber was maximized to reduce partial volume effects from the ventricle 
walls; 2) the slice was the farthest away from the mitral valve to reduce flow effects 
thereby minimizing artifacts due to cardiac motion; and 3) an automated syringe pump 
was used to ensure reproducible delivery of the contrast agent to all mice. These details 
are critical to measure individual VIFs that will ultimately produce a population VIF.  
In Fig. VI-1, the population VIFs for Gd-DTPA and P846 have a relatively low 
standard deviation at the peak of the curve which suggests these individual VIFs are 
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reaching very similar peak concentration in the LV. In the Gd-DTPA and P846 data, the 
higher variability in the wash-out manifests itself primarily in the ve parameter while the 
smaller variability at the peak and wash-in phase seem to be reflected in the high 
correlations between K
trans
 measures.  
In the ROI analysis, correlations and trends for K
trans
 and ve are similar for the 
standard and extended models as well as the different contrast agents. K
trans
 (both ST and 
EX) displays a high correlation, indicating that parameters produced using the VIFpop are 
very similar to those that are produced using the VIFind. For ve, however, the CCCs are 
lower, which is most likely an indirect manifestation of the larger wash-out variability 
seen in Fig. VI-1. However, the ROI-based analysis did not appear to be as sensitive to 
this variability as the voxel-based comparison. The ROI-based analyses suggest that 
using a population VIF produced statistically similar parameters, especially for K
trans 
(ST 
and EX) indicated by a correlation with unity > 0.90; additionally, the resulting power 
analysis suggests an increase of at most 35% in the population can preserve the power 
when using a population VIF versus an individual VIF. For ve and vp parameters, the 
results did not follow a similar trend as they tended to drift from unity. However, these 
parameters show a large degree of linearity, which indicates that an overall shift in the 
wash-out period of the VIFind compared to that of the VIFpop would produce parameters 
that were linearly shifted as well (either over- or underestimated). While this is not ideal, 
the strong linearity of these parameters suggests that the VIF shape is similar. Thus, if the 
VIFpop was used in a treatment study, for example, the pre- and post-treatment values for 
ve would both be potentially over- or underestimated but the relative change in the 
parameter may remain the same. Interestingly, since the power analysis relies on inter- 
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and intra-subject variability, in order to achieve the same power in measuring ve using 
Gd-DTPA, no increase in population is required; in fact, 10-15% less animals can be used 
(see Table VI-2).  
The same cannot be said for P846, which requires the population size to double if a 
population VIF is used and ve is the primary metric (Table VI-2). One of the goals of 
using larger contrast agents such as P846 is to differentiate flow and permeability 
characteristics in the tissue. Gd-DTPA is small (~ 0.5 kDa); thus, clearance and 
extravasation to the tissue may be more flow-limited when compared to a larger agent. 
However, by inspecting the VIFs in Fig. VI-1, it is evident that the larger contrast agent 
provides a longer peak and wash-out period. The permeability of tissue and the ability to 
clear a contrast agent are characteristics that are unique to each animal; thus, for smaller 
agents such as Gd-DTPA the differences in permeability and clearance do not have as 
great an impact on the VIFind or VIFpop. However, with P846 the permeability and 
clearance rate become a more important factor in both the VIFind and tissue curves; 
hence, the greater disparity between parameter pairs such as ve and vp, indicate that the 
variability in permeability and clearance for P846 between animals may lead to greater 
differences between the VIFind and VIFpop.  
The voxel-based data follows a similar trend as the ROI-based analysis; however, the 
sensitivity to the differences between parameter pairs is magnified, as illustrated in Fig. 
VI-3 and VI-4. The parametric maps show that, in this particular mouse, the wash-in and 
peak phase of the VIF are similar, thus producing K
trans
 (both ST and EX) data points that 
fall along the line of identity.  In this mouse, the ve and vp parameters obtained from the 
VIFpop are always overestimated from the parameters produced from the VIFind. The plots 
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show this linear increase, which is an indirect demonstration of the VIFind curve being 
overestimated by the VIFpop. It is also worth noting that, as mentioned in the Methods 
section, some voxel signal data were fit using the VIFind but could not be fit with VIFpop 
(i.e., the parameters returned using VIFpop were outside a physiologically relevant range). 
These data were not included in the above analysis as these “outlier” data tended to 
severely skew linear regression analysis. Instead, these occurrences were tallied to show 
the frequency of the occurrences within each mouse and shown in Table VI-11. 
 
Additional results comparing a fitted VIFind and a fitted VIFpop showed similar 
statistical trends (refer to Tables VI-7 and VI-8) to that of comparing the raw VIFind and a 
raw VIFpop suggesting than if bi-exponentially fit data is used for the VIF, the 
conclusions discussed here remain valid. By examining a temporal resolution that better 
reflects a more realistic application of obtaining high resolution, high signal to noise 
scans, it was concluded that while the downsampled data may produce more inaccurate 
parameter values (refer to Table VI-9) but the comparative trends remain the same; in 
TABLE VI-11 
ILL-FIT VOXEL DATA FOR GD-DTPA AND P846. 
Mouse 
ID 
Gd-DTPA P846 
Percentage of voxels 
fit only by VIFind but 
not VIFpop 
Percentage of voxels 
fit only by VIFind 
but not VIFpop 
1 0 0 
2 3 0 
3 0 0 
4 0 0 
5 0 0 
6 0 11 
7 0 5 
8 0 8 
9 0 2 
10 52 na 
11 42 na 
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other words, the absolute values of the parameters changed but the differences between 
parameters found using the downsampled data/VIFind and downsampled data/VIFpop were 
similar to those reported above using the tissue curve that was sampled more frequently 
(refer to Table VI-10). As noted in the results examining the effects of temporal 
resolution, the comparison of kinetic parameters using a VIFpop relative to the VIFind is of 
interest; the physiological meaning of these parameters and how they change under 
various conditions is important but is beyond the focus of this current work.   
The results of this study indicate that for animals imaged with Gd-DTPA, K
trans
 
(obtained by both the standard and extended models) estimated using a population based 
VIF have a very high correlation with K
trans
 parameters estimated using an individual VIF 
on both a global (ROI) and local (voxel) level. An increase 15-35% in population 
(potentially only 2-4 animals) can preserve the power if the VIFpop is used instead of the 
VIFind.  Since K
trans
 is typically the primary metric for the majority of DCE-MRI studies, 
this work supports the use of a population derived VIF obtained with a strict injection 
protocol and additional animals to preserve the power of the study.  
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CHAPTER VII 
 
 
ASSESSING THE EFFICACY OF A NOVEL JAK2 INHIBITOR (AZD 1480) USING 
DIFFUSION WEIGHTED AND DYNAMIC CONTRAST-ENHANCED  MAGNETIC 
RESONANCE IMAGING COMPARED TO POSITIVE (AZD 2171) and VEHICLE 
CONTROLS 
 
 
  
 
Introduction 
As mentioned previously in Chapter III, Jak2 inhibition reduces the levels of Stat3 
that is persistently activated in many cancer lines; Stat3 is responsible for the 
transcription of factors that promote tumor growth (1), halt apoptosis pathways (1,2), and 
increase angiogenic activity (3). AZD 1480 is a novel drug that acts as small molecule, 
inhibiting Jak2 and thereby suppressing levels of Stat3 within tumors (4). Both diffusion 
weighted magnetic resonance imaging (DW-MRI) and dynamic contrast enhanced MRI 
(DCE-MRI) have been used frequently to monitor cancer treatment, as discussed in 
previous chapters. Since two of the pathways affected by Jak2 inhibition involve reduced 
proliferation/increased apoptosis and reduced angiogenic activity, this work seeks to 
assess the utility of DW-MRI and DCE-MRI  in assessing the efficacy of AZD 1480, a 
novel Jak2 inhibiting drug, compared to a potent anti-angiogenic drug (AZD 2171)  (5) 
and vehicle controls at early treatment time points. 
 
Methods 
Tumor Model 
Calu-6 human lung carcinoma cells were grown according to the protocol developed 
in Wedge et al (6). Briefly, the cells were grown in a media containing 10% FCS and 2 
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mM L-glutamine in Eagle‟s Minimal Essential Medium with 1% sodium pyruvate (100 
mM) and 1% non-essential amino acids. Cells growing at 80% confluence were 
harvested, and a single cell suspension containing 1 × 10
6
 cells suspended in 100 µL of 
medium were injected subcutaneously on the flank. Tumors were grown for 15 to 20 days 
to reach a size of approximately 200-250 mm
3
 before imaging. 
 
Animal Model 
Thirty adult female fox nu/nu (8-10 weeks of age) were purchased from Charles River 
Laboratories, housed in pathogen-free facilities with a 12-hour light/dark
 
cycle (6 AM–6 
PM), and provided with rodent chow and tap
 
water ad libitum. For DCE-MRI studies, a 
26-gauge jugular catheter was surgically implanted to allow for delivery of the contrast 
agent. All animals were imaged at three time points: a baseline scan was acquired prior to 
any treatment, and then two subsequent sessions at day 3 and day 5 after the initiation of 
treatment. The mice were then humanely sacrificed for histological analysis of tumor 
tissues. During all imaging procedures, the mice were anesthetized using a 2%/98% 
isoflurane/oxygen mixture. Body temperature was maintained via a flow of warm air 
through the magnet bore, and temperature and respiratory rate were monitored throughout 
the entire experiment. All procedures in the experiment were reviewed and approved by 
our Institutional Animal Care and Use Committee.  
 
Treatment 
The vehicle for AZD 1480 was prepared using 0.1 mL of Tween80 (Sigma Aldrich, 
St. Louis, MO), 0.5 g of methylcellulose powder and 100 mL of distilled water stirred 
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overnight. A vehicle was added to a dose of 50 mg/kg of AZD 1480 such that the 
administered volume was 10 mL/kg. HCl was added to the drug to ensure the pH was 2.0, 
following the manufacturer‟s recommended protocol. The vehicle for AZD 2171 was 
prepared using 0.1 mL of Tween80 added to 100 mL of distilled water. Vehicle was 
added to a dose of 6 mg/kg such that the administered volume was 10 mL/kg. All drugs 
and vehicles were stored at 4° C. Thirty mice were randomly assigned to one of the 
following three treatment groups once tumor volumes were approximately 200 mm
3
: 50 
mg/kg AZD 1480, p.o. q.d., 6 mg/kg, AZD 2171 p.o. q.d., and vehicle control, p.o. q.d.  
 
Data Acquisition 
DW-MRI 
Animals were imaged on the 9.4T MR scanner (Varian, Palo Alto, CA) with a 38-mm 
quadrature coil (Varian, Palo Alto, CA) at all three time points. Due to technical issues, 
three animals had day 5 data and four animals had day 3 data acquired on a 7T MR 
scanner (Varian, Palo Alto, CA) using identical protocols. A gradient echo scout 
sequence was used to locate the tumor tissue. Once the region of interest was located, 
fifteen slices were imaged (1 mm thick, interleaved) with diffusion weighting using a 
gated and navigated pulsed gradient spin echo sequence.  DW-MRI parameters were as 
follows: TR\TE\α = 2000 ms\42 s\15°, acquisition matrix = 1282, FOV = (35 mm)2, and 
NEX = 2 with Δ = 35.00 ms and  δ =5.00 ms for b-values of 150.88, 500.2, and 800.22 
mm
2
/s.  The equivalent diffusion distance examined was approximately 13 µm as 
described in Chapter IV. 
 
 90 
DCE-MRI 
After DW-MRI, pre-contrast T1 maps were obtained using an inversion recovery 
snapshot FLASH (Fast Low Angle SHot) gradient echo sequence with an adiabatic 
inversion pulse over nine inversion times (TI) ranging from 20 – 10000 ms. Imaging 
parameters were as follows: TR\TE \α= 12100 ms\ 3.44 ms\15° and NEX = 4, FOV = 
35 mm
2
, and matrix = 128
2
. The data were then fit to Eqn. (II-10), to obtain T1 maps for 
all fifteen slices of data. The DCE-MRI protocol employed a T1-weighted, gradient echo 
sequence to obtain 40 serial images for each of fifteen axial planes in 18 minutes of 
imaging. The parameters were as follows: TR\TE\α = 100 ms\2.83 ms\25°, NEX = 2, with 
the same acquisition matrix and FOV as for the T1 map. A bolus of 0.1 mmol/kg Gd-
DTPA was delivered over 2.5 seconds with an automated Harvard pump (2.4 mL/min) 
via a jugular catheter beginning after the acquisition of the fifth dynamic image.  
 
Data Analysis 
DW-MRI 
The derivation for the signal intensity relationship with diffusion weighted data was 
described in Chapter IV. Briefly, the diffusion weighted images acquired at three separate 
b values, 150.88, 500.2, and 800.22 mm
2
/s,were fit to Eqn. (IV-9) to extract the ADC 
values at every ROI and voxel location.  
 
DCE-MRI 
Data collected for the T1 map were fit using a nonlinear least squares method in 
Matlab 2008a (The Mathworks, Natick, MA, USA) to Eqn. (II-10). Once pre-contrast T1 
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maps were calculated, Eqn. IV-2 was used to extract pharmacokinetic parameters of K
trans
 
and ve (7). The derivation of this model is described in Chapter IV. The signal time 
course from the tissue for each voxel was fit using a nonlinear least squares fit to Eqn. 
(IV-2) by incorporating 1) the relationship between the signal and the initial R1/T1 values 
by means of the method described by Landis, et al., Eqn. (VI-1) (8), 2) the fast exchange 
limit (FXL) model with relaxivity for Gd-DTPA at 9.4T was found to be 4.8  mM
-1
s
-1
 
(unpublished results, see Figure V-1) and a hematocrit value of 0.45, based on literature 
values (9), and 3) a population-derived VIF or Cp(t) derived from a cohort of ten fox 
nu/nu mice found identical to the study described in the previous chapter.   
 
Histology 
On day six (one day after the final imaging session), animals were dosed and 
sacrificed using CO2 two hours later. These samples were taken on the final day to mimic 
the imaging timeline; this ensured that the histology and molecular markers would reflect 
two hours after dosing just as when imaging was performed. The tumor tissue was 
excised, placed into tissue cassettes, and soaked in 10% Formalin (Fisher, Pittsburgh, PA) 
for 24-48 hours. The tissue was then store in 70% ethanol until the all tumors from this 
study were excised. Subsequent immunohistochemistry was performed at the 
AstraZeneca facility in Waltham, MA. Samples were paraffin embedded and sectioned at 
5 µm thickness. Immunohistochemistry was performed on the Ventana Discovery XT 
Autostainer using the standard CC1 protocol. In order to verify proper AZD 1480 dosing, 
samples were stained with phosphoylated Stat3 (pStat3) antibody (Cell Signaling 
Technology, Danvers, MA). Additionally cellular proliferation, apoptosis, microvessel 
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density, and cell density estimates were found using Ki-67 (Cell Signaling Technology, 
Danvers, MA), cParp (Cell Signaling Technology, Danvers, MA), CD31 (Cell Signaling 
Technology, Danvers, MA) and hematoxylin/eosin (H&E) staining (Ventana, Tucson, 
AZ), respectively. 
From the CD31 stained slides, microvessel density was calculated by using the 
Aperio (Vista, CA) Microvessel Analysis software; briefly, the software was tuned to 
detect the CD31 stain color and the size of the detected vessels. The algorithm then basis 
vessel selection on the endothelial areas compared to the lumen areas, and how the 
regions should be joined together to form a vessel. The number of vessels detected were 
divided by the area of the field of view in order to determine the microvessel density. 
Additionally, Aperio digital histology images of the tumor were acquired at 20× 
magnification. The Positive Pixel Count Algorithm, developed by Aperio, was used to 
create maps of intra- and extracellular regions based on intensity thresholding; briefly, 
based on the intensity of the stains, images were thresholded into four categories: positive 
(e.g., hemotoxylin), strong (e.g., eosin), weak (e.g., eosin), and no staining (e.g., 
extracellular regions). A region was drawn to encompass the entire slice of histology data 
and thresholded as described above. Statistics summarizing the thresholding that include 
total region area (AROI) and total stained area (Astain) were used to determine the 
percentage of extracellular (EC) space as shown below: 
( )
( ) ROI stain
ROI
A A
EC % 1 100
A
.  (VII-1) 
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Statistical Analysis 
In order to assess group changes in K
trans
, and ve, an ROI was manually drawn on the 
center slice for each tumor at each time point. The average signal intensity was then fit to 
Eqn. (IV-2) to obtain parametric values for each animal at baseline, day 3, and day 5. The 
same ROIs were applied to diffusion-weighted data collected at b values of 150.88, 
500.2, and 800.22 mm/s
2
. The data were then fit to Eqn. (IV-9), as described above, to 
obtain ADC values for all mice at all time points.  Before being placed into the 
appropriate treatment group for analysis, the integrity of the data was examined by using 
either muscle tissue (DCE-MRI) or water phantom data (DW-MRI) as shown in Fig. VII-
1. Briefly, if the muscle curve did not qualitatively follow characteristics of a rapid wash-
in and wash-out of CA or if physiologically implausible parameters were returned, the 
injection was deemed unsuccessful and the DCE-MRI data was not used. Similarly, if the 
slice used in the DW-MRI comparison had a phantom ADC value outside the range of 
0.003 mm
2
/s ± 15% (experimentally-derived ADC of free water at 34° at 9.4T), then the 
tumor ADC data was also not used. For each treatment group, the average and standard 
error (1.96 × standard deviation /√n, where n is the number of samples) were computed. 
The percent change from baseline for each animal was also computed, and the average 
and standard error were calculated.  A Wilcoxon signed rank test was used to determine 
significant differences between each treatment group (both absolute and percent change 
data) (10). Histological data were quantified using pathological scoring and compared 
with all imaging metrics. 
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Results 
In total, N = 12 / N = 10 / N = 9 mice were imaged at three time points for the AZD 
2171 / AZD 1480 / CTL groups, respectively. For the DCE-MRI group analyses, N2171 = 
7 / N1480 = 8 / NCTL = 6 animals were used while N2171 = 5 / N1480 = 9 / NCTL = 7 animals 
were used in the ADC group analysis. The tumor volume changes for all animals are 
shown in Fig. VII-2, where the square/solid line indicates animals treated with AZD 
2171, the circle/dashed line indicates animals treated with AZD 1480 and the 
triangle/dashed line represents animals in the CTL group. The vertical lines are 1.96  
standard error for each respective group. 
 
Fig.VII-1. The water phantom in the top right of the figure was used to ensure that 
ADC values for the interrogated slice were accurate. An example of the DW-MRI fit 
of this phantom data is shown in the lower left corner. Muscle tissue was used to 
verify DCE-MRI data integrity. An example of the muscle tissue curve and subsequent 
fit is shown in the lower right. 
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Animals that did not have a characteristic muscle curve (potentially from a damaged 
catheter line) or inaccurate water phantom ADC values (potentially caused by ghosting 
artifacts) were excluded from further analyses.  Average phantom and muscle data are 
shown in Fig. VII-3.  
 
Fig.VII-2 Volumetric data for all animals used in each treatment group. The solid 
circles/solid line represents the AZD 2171 group while the open circle/dashed line 
represent the AZD 1480. The control group is represented by the triangle/dashed line 
with the vertical lines indicating 1.96  standard error for each time point.  
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Fig. VII-3.  The average K
trans
 (a) and ve (c)  from muscle tissue and ADC from 
the water phantom (b) for each treatment group (AZD 2171 (●), 1480 (○), and 
Control (▲)) where the standard error bars are represented by the vertical bars. 
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Group Analyses 
The results of the percent change in the group analyses are displayed in Fig. VII-4 
(figures displaying individual sample percentages are shown in the Appendix). The AZD 
2171 treatment group is denoted by the square and solid line; the AZD 1480 treatment 
group is denoted by the circle and dashed line while the control (CTL) group is 
represented by the triangle marker and dashed line. The vertical lines indicate the 
standard error for each treatment group while the „*‟ denotes significance (p-value < 
0.05) from baseline measurements in the same group.  
Animals treated with the positive control, AZD 2171,  showed significant decreases 
in K
trans 
at both day 3 and day 5 with an average percent difference of -29% and -53%, 
respectively (depicted in Fig VII-4 (a)). The average percent differences in the AZD 1480 
treatment group were -21% and -23% for each post-treatment time points while the CTL 
group showed stable decreases of 26 percent at both subsequent time points. No 
significant differences were found in either AZD 1480 or CTL groups at either post-
treatment time points for K
trans
. Absolute K
trans
 values for these treatment groups are 
listed in Tables VII-1 through VII-3. 
 
TABLE VII-1 
ABSOLUTE K
TRANS
 VALUES IN THE AZD 1480 TREATMENT GROUP. 
ID Baseline Day 3 Day 5 
CD31 Scoring and 
Description 
(min
-1
) (min
-1
) (min
-1
) (if available) 
1 0.047 0.033 Na 2+ peripheral vessels 
2 0.064 0.039 na na 
 3 0.088 0.155 0.059 3+ 
 4 0.051 0.026 0.026 1+ necrotic tissue 
5 0.122 0.069 0.047 3+ attenuated vessels 
6 0.040 0.019 na 1+ 
 7 0.036 0.046 0.042 1+ 
 8 0.039 0.010 0.037 1+ slit-like morphology 
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In Fig. VII-4 (b), the percent change in ADC shows that both treatment groups 
demonstrate an increasing trend with a significant increase for the AZD 1480 at both day 
3 (63%) and day 5 (49%) post-treatment. While the AZD 2171 group shows an increase 
on day 5 for ADC, only three animals were available at this final time point so that 
statistical significance could not be achieved. Also of note, the CTL group trended 
negatively, suggesting that apparent diffusion decreased as the tumor grew. Absolute 
ADC values for the three treatment groups are listed in Tables VII-4-6. 
TABLE VII-2 
ABSOLUTE K
TRANS
 VALUES IN THE AZD 2171 TREATMENT GROUP. 
ID Baseline Day 3 Day 5 
CD31 Scoring and 
Description 
(min
-1
) (min
-1
) (min
-1
) (if available) 
1 0.050 0.036 0.012 na 
 2 0.054 0.056 0.066 2+ attenuated vessels 
3 0.041 0.028 na 1+ attenuated vessels 
4 0.052 0.021 0.021 1+ attenuated vessels 
5 0.094 0.089 0.031 na 
 6 0.046 0.040 0.022 1+ necrotic tissue 
7 0.068 0.019 0.009 1+ slit-like morphology 
 
TABLE VII-3 
ABSOLUTE K
TRANS
 VALUES IN THE CONTROL GROUP. 
ID Baseline Day 3 Day 5 
CD31 Scoring and 
Description 
(min
-1
) (min
-1
) (min
-1
) (if available) 
1 0.048 0.053 0.055 3+ 
 2 0.052 0.019 0.021 2+ 
 3 0.096 0.054 0.060 3+ 
 4 0.104 0.052 0.037 3+ diffuse distribution 
5 0.062 0.071 0.073 na 
 6 0.030 na 0.022 na 
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In the final panel of Fig. VII-4 (c), the group changes for ve  are demonstrated. No 
significant changes in ve were illustrated with the exception of day 5 of AZD 2171 
treatment, which reflected a significant decrease at this time point. The absolute values of 
ve found for all animals in each treatment group are listed in Tables VII-7 through 9. 
TABLE VII-6 
ABSOLUTE ADC VALUES IN THE CONTROL GROUP. 
ID 
Baseline Day 3 Day 5 
(× 10
-4
 mm
2
/s)  (× 10
-4
 mm
2
/s)   (× 10
-4
 mm
2
/s)   
1 8.90 na 6.84 
2 8.55 5.23 4.07 
3 7.48 na na 
4 3.98 9.03 na 
5 5.17 8.16 4.08 
6 7.57 6.66 na 
7 6.01 3.59 na 
 
TABLE VII-5 
ABSOLUTE ADC VALUES IN THE AZD 2171 TREATMENT GROUP. 
ID 
Baseline Day 3 Day 5 
(× 10
-4
 mm
2
/s)  (× 10
-4
 mm
2
/s)   (× 10
-4
 mm
2
/s)   
1 7.32 4.66 7.25 
2 7.71 8.72 na 
3 6.85 3.76 10.1 
4 6.70 10.1 8.46 
5 3.95 7.04 Na 
 
TABLE VII-4 
ABSOLUTE ADC VALUES IN THE AZD 1480 TREATMENT GROUP. 
ID 
Baseline Day 3 Day 5 
(× 10
-4
 mm
2
/s)  (× 10
-4
 mm
2
/s)   (× 10
-4
 mm
2
/s)   
1 3.61 6.85 8.76 
2 5.12 6.29 na 
3 6.41 na 11.0 
4 4.79 8.55 4.80 
5 7.17 7.64 12.2 
6 5.98 na 9.32 
7 9.24 na 11.6 
8 6.01 na 6.59 
9 5.61 na 4.47 
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Fig. VII-4. Each panel demonstrates the percent change from baseline for K
trans
, 
ADC, and ve, respectively, from a center slice ROI where AZD 2171 (), 1480 
(●), and Control (▲) with the standard error bars are represented by the vertical 
bars. P-values less than 0.05 are noted by the *. Statistical significances were 
found for K
trans
 in the AZD 2171 treatment group while AZD 1480 day 3 and day 
5 data showed significant increases in ADC. A significant decrease was found for 
ve in the AZD 2171 treatment group. 
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Three representative curves (representing each time point) from a mouse in each 
treatment group are shown in Fig. VII-5. The dynamic data and curve fit (in black) were 
TABLE VII-9 
ABSOLUTE VE VALUES IN THE CONTROL GROUP. 
ID 
Baseline Day 3 Day 5 
      
1 0.347 0.478 0.526 
2 0.236 0.231 0.344 
3 0.551 0.584 0.395 
4 0.350 0.399 0.268 
5 0.276 0.259 0.377 
6 0.214 na 0.246 
 
TABLE VII-8 
ABSOLUTE VE VALUES IN THE AZD 2171 TREATMENT GROUP. 
ID 
Baseline Day 3 Day 5 
      
1 0.536 0.544 0.192 
2 0.284 0.277 0.263 
3 0.484 0.547 na 
4 0.292 0.395 0.294 
5 0.393 0.321 0.322 
6 0.248 0.405 0.146 
7 0.656 0.129 0.206 
 
TABLE VII-7 
ABSOLUTE VE VALUES IN THE AZD 1480 TREATMENT GROUP. 
ID 
Baseline Day 3 Day 5 
      
1 0.966 0.748 na 
2 0.477 0.668 na 
3 0.456 0.563 0.354 
4 0.661 0.726 0.880 
5 0.692 0.353 0.721 
6 0.279 0.866 na 
7 0.333 0.450 0.290 
8 0.126 0.273 0.207 
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taken from baseline while the red and blue fit lines indicate day 3 and day 5 data, 
respectively. Panel (a) shows the dramatic efficacy of AZD 2171 on K
trans
 (denoted by the 
arrow) while panel (b) and panel (c) reiterate the group average results for AZD 1480 and 
CTL, respectively. In both (b) and (c), K
trans
 changes very little or without trend (as 
denoted by the arrows), whereas this is a marked decrease in this parameter in panel (a). 
 
 
Histogram Analyses 
To further explore the efficacy of K
trans
, ADC, and ve to report on these treated 
animals, parametric maps and histograms were constructed. Fig. VII-6 illustrates a panel 
of K
trans
 maps for each treatment group (rows: AZD 2171, AZD 1480, and CTL) at each 
time point (columns: baseline, day 3, and day 5). The corresponding histograms for the 
slice data is represented in the final column. Both the maps and the histograms confirm a 
significant decrease in K
trans
 values for the AZD 2171 treatment group, shown by the 
arrow (a, b, c, and d) while little change or trend is noted in the AZD 1480 group (e, f, g, 
 
Fig.VII-5 Example DCE-MRI curves from each treatment group. Panel (a) shows a 
subject from the AZD 2171 treatment group with the black line indicating the 
baseline, the red line indicating day 3 data, and the blue line representing day 5 data. 
As noted by the arrow, there is dramatic decrease in K
trans
 for the AZD 2171 group. 
Panel (b) shows ROI curves from the AZD 1480 group with the arrow showing that 
no specific pattern in K
trans
 can be detected; similarly, panel (c), representing the 
control group, shows little detectable change in K
trans
 values. 
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and h). Interestingly, in this CTL animal, higher K
trans
 values are found at the day 5 time 
point, as shown by the arrow (i, j, k, and l). 
  
ADC maps and histograms were also constructed and displayed in Fig. VII-7.  In a 
similar fashion, the treatment groups are displayed in the rows (AZD 2171, AZD 1480 
and CTL groups) while each column represents the imaging time points (baseline, day 3, 
and day 5).  The ADC maps do not show a dramatic difference in the AZD 2171 animal 
(a, b, c, and d) while there is a clear increase in ADC values for the AZD 1480 animal (e, 
f, g, and h). The CTL group (i, j, k, and l) shows a decrease ADC values that reflect the 
group analyses mentioned above. 
 
Fig. VII-6. K
trans
 parametric maps for representative mice from each treatment 
group. The columns indicate baseline, day 3 and day 5 time points while each 
row shows the AZD 2171 (a-d), AZD 1480 (e-h), and Control groups (i-l). In 
panel d, the arrow emphasize an increase in lower K
trans
 values by day 5 unlike in 
panel l where the arrow indicates more of an increase in higher K
trans
 values in the 
Control group. 
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The final series of panels, shown in Fig VII-8, displays ve data from represented 
animals from the treatment groups in a similar fashion. No trends or correlations are 
evident with this parameter. Interestingly, this parameter maintains very high values at all 
time points for all treatments. Some voxels surpassed the physiological boundary (ve = 1) 
which were exempt from analyses; additional comments about this phenomena can be 
found in the subsequent chapter.  
 
Fig. VII-7. ADC parametric maps for representative mice from each treatment 
group. The columns indicate baseline, day 3 and day 5 time points while each 
row shows the AZD 2171 (a-d), AZD 1480 (e-h), and Control groups (i-l). 
Supporting the group findings, a increase in ADC can be seen in panel h while the 
Control group shifts to a lower ADC distribution in panel l. 
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Histological Correlation 
Since Jak2 inhibition by AZD 1480 reduces Stat3 activity (as discussed in Chapter 
III), samples were stained with phosphorylated Stat3 (pStat3); all AZD 1480 samples 
were found to significantly inhibit pStat3 activity while AZD 2171 and control groups 
yield normal levels of expression.  In order to verify the imaging results, stains for CD31 
(as a marker for microvasculature) were acquired, and the pathologists scoring and 
comments are listed in Table VII-1 through VII-3. A histogram of the CD31 scoring for 
each treatment group is shown in Fig. VII-9 (a). A CD31 scoring ranges from 1+, which 
indicates little to no vasculature while a scoring of 3+ indicates a heavily vascularized 
section of tissue. As noted by the comments as well as the histogram, the AZD 2171 
treated group showed reduced vasculature and distinct changes in vessel morphology that 
indicated vascular collapse (e.g., as the vessels collapsed, the vessel structures resembled 
 
Fig. VII-8. ve parametric maps for representative mice from each treatment group. 
The columns indicate baseline, day 3 and day 5 time points while each row shows 
the AZD 2171 (a-d), AZD 1480 (e-h), and Control groups (i-l).  
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more of a “slit” – like morphology). However, the distribution for CD31 scoring for AZD 
1480 seems equally distributed into all scoring categories, similar to the CTL group, with 
only some tumors depicting morphological changes indicating “attenuated” vessels.   
 
 
Fig. VII-9.  Panel a shows a histogram of CD31 data depicting the number of 
samples from each treatment group scored 1+ (low/attenuated vasculature), 2+ 
(somewhat vascularized) or 3+ (highly vascularized). The CD31 findings support 
the group analyses in that vasculature was reduced in AZD 2171 while 
vasculature in AZD 1480 showed no significant decrease in K
trans
 or CD31. In 
panel b, microvessel density was calculated for all the samples in each treatment 
group. Each „•‟ represents a sample with the bold solid line being the mean and 
the error bars above and below are ± (1.96  standard error). While both 
AZD2171 (p = 0.13) and AZD1480 (p = 0.42) groups trended toward reduced 
microvessel density relative to the control group, no significance was reported. 
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In order to quantify the vasculature in histology, microvessel density was calculated from 
the CD31 staining, described in the Methods section, and the results are shown in Figure 
VII-9 (b). While no significant differences were detected in either treatment groups from 
the control group, the control group displays a larger variation in measurements than both 
treatment groups. Interestingly, both AZD 2171 and AZD 1480 groups have similar 
microvessel density as measured by CD31 after the last imaging time point. 
Additional immunohistochemistry analyses for cellular activity included H&E, Ki-67, 
and cParp staining; the results of these analyses are shown in Fig. VII-10. Panel (a) 
demonstrated the extracellular space fraction (EC (%)) on H&E stained slides, calculated 
as described in the Methods section, for each group. A significant increase in EC (%) was 
found between the AZD 1480 treatment group and the control group while the AZD 2171 
showed an increasing trend in EC (%). To quantify the effects on proliferation, Ki-67 was 
used to identify the percentage of cells that was actively proliferating at the last imaging 
time point; the results for all three groups are shown in panel (b), and no statistical 
significances were reported between treatment and control groups. Finally, cParp, a 
marker for apoptosis, was quantified as percentage of cells that stained positive for 
apoptotic activity. The results of this study are shown in Fig. VII-10 (c) with a 
statistically significant (p = 0.036) increase in cParp staining for the AZD 1480 treatment 
group compared to the control group. Sample slides from CD31, Ki-67, and cParp are 
shown in Fig. VII-11. 
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Fig. VII-10.  Panels a, b, and c display cell density, Ki-67, and cParp staining 
results, respectively for each group. Each „•‟ represents a sample with the bold 
solid line being the mean and the error bars above and below are ± (1.96  
standard error). Panel (a) displays the cell density results as determined by H&E 
staining while panel (b) shows percentage of cells that stained positive for Ki-67 
activity. Similarly, panel (c) depicts the percentage of cells that stained positive 
for cParp activity. 
 109 
Discussion 
The use of a Jak2 inhibitor as an anti-cancer treatment has been shown to interfere 
with several oncogenic pathways. Downstream effects of inhibiting Jak2 include 
prohibiting angiogenesis (2,3), decreasing cellular proliferation (1), and increasing 
apoptotic activity (1,2); thus, Jak2 inhibitors such as AZD 1480 have been shown as 
effective methods of inhibiting tumor growth (4). One of the unique advantages of 
imaging tumor physiology is the ability to capture changes prior to any 
palpable/volumetric changes in tumor growth. Thus, the goal of this study was to 
examine the efficacy of AZD 1480 using two imaging techniques that report on the 
physiologic attributes of angiogenesis and cellularity. 
 
 
Fig. VII-11.  Sample staining for CD31 (first row), Ki-67 (second row), and cParp 
(last row) for the AZD 2171 treatment group (first column), AZD 1480 treatment 
group (second column), and Control group (last column). The brown staining shown 
in the CD31 staining indicates a positive stain for CD31 on endothelial cells while a 
brown staining in the Ki-67 images indicates cells that are in a proliferative state. The 
brown staining for the cParp images indicate cells positive for the Parp cleavage 
typically  characterized by cells undergoing apoptosis. 
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The group changes demonstrated in this work indicate that day 3 and day 5 of a once 
per day dose (50 mg/kg) of AZD 1480 is possibly too early to see any anti-angiogenic 
effects. Compared to the positive control AZD 2171, which is a potent anti-angiogenic 
drug, changes in the vasculature of the AZD 1480 group were not evident as supported by 
immunohistochemistry.  
Interestingly enough, the more sensitive measure for AZD 1480 treatment seemed to 
be ADC. Significant increases in ADC were indicated in the group study and shifts were 
noted on a voxel-by-voxel level. Additionally, while tumor volume gave no significant 
indications of efficacy for this group, immunohistochemistry indicated a significant 
increase in apoptosis and extracellular space (EC (%)) in this treatment group. Thus, 
cellular level changes could be identified prior to any anti-angiogenic affects could be 
noted. In previous work, changes in vascularity have been seen as early as day 6 with this 
dosing regimen in this cell line by CD31 staining (D. Huszar, unpublished results). One 
could hypothesize that if the treatment and subsequent DCE-MRI data were taken out 
over a longer period of time, significant decreases in K
trans
 might be noted, but logistics 
could not permit a longitudinal study of that length for this work. Since ADC was 
determined as a sensitive parameter, it appears that Jak2 inhibition initially impacts 
cellular function within the tumor with a potential latent affect on vascularity. 
As discussed in Chapter IV, DW-MRI has been shown to correlate with cell density 
measures in cancer (11-14). In this study, significant difference was found in extracellular 
space (indirectly identifying cell density) measures from H&E in the AZD 1480 group; 
however, ve did not illustrate any significant trends other than a demonstrating a 
significant decrease on day 5 for the AZD 2171. With a significant change in cParp 
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(apoptosis surrogate) and EC (%) and no difference in Ki-67 (proliferation marker), one 
could hypothesize that the changes in ADC are primarily induced by pro-apoptotic 
activity. At a molecular level, significant changes in cParp indicate apoptotic activity; 
Parp is a protein involved in DNA repair, differentiation, and chromatin structure 
formation. During apoptosis, caspase-3 (mentioned in Chapter III) cleaves this protein. 
Thus, the cleaved fragment of Parp (cParp) indicates caspase/apoptotic activity (15). 
Regretfully, these endpoint histology measures do not allow the change in these 
histology parameters to be compared to the changes in imaging parameters. However, the 
relationship between these histology endpoint measurements and the imaging data is 
explored in more detail in the following chapter (Chapter VIII). As mentioned earlier, 
ADC can be affected by several cellular/extracellular activities such as changes in active 
transport, blood flow, and tissue re-organization (16). These changes can also be transient 
with treatment activity; for example initial cellular swelling and reduced blood flow may 
lead to lower ADC values earlier in treatment (17). As cells begin to die, edema, reduced 
cell density, and tissue reorganization may lend to an increase in ADC, as seen frequently 
during treatment of malignant tumors (16). Thus, it is possible that the change in ADC 
reflects a change in tissue reorganization as apoptosis increases. Similarly, cell density 
correlation with ADC may be confounded by changes in blood flow and perfusion in the 
positive control AZD 2171. This anti-angiogenic drug can cause vessel attenuation and 
degradation leading to vessel/tissue component reorganization. While no significant 
changes in ADC were noted in the AZD 2171 group, the ADC at day 5 demonstrated an 
increasing trend as did the percent extracellular space (EC (%)). Thus, it appears that 
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ADC reports on different cellular / tissue properties based on both cancer and treatment 
model; regardless, it seems to be a more sensitive measure for drugs inhibiting Jak2. 
The goal of this study was to assess the efficacy of AZD 1480 using parameters from 
both DCE-MRI and DW-MRI. As anticipated, K
trans
, an indicator of blood flow/perfusion 
reported significant changes in the anti-angiogenic drug, AZD 2171, treatment group 
from baseline measurements; this finding was also supported by histology. K
trans
 did not 
seem to reliably report any treatment response for AZD 1480 but significant changes in 
ADC at both day 3 and day 5 post-treatment and significant apoptotic activity and 
increased extracellular fraction indicated that cellular activity may be a better biomarker 
for early treatment response using a Jak2 inhibitor. 
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CHAPTER VIII 
 
 
PRELIMINARY CROSS-CORRELATION OF CELL DENSITY MEASUREMENTS 
USING DCE-MRI, DW-MRI AND HISTOLOGY IN SUBCUTANEOUS CALU-6 
XENOGRAFTS 
 
 
 
Introduction 
    
In Chapter IV, it was discussed that the apparent diffusion coefficient (ADC) maps 
obtained from DW-MRI have not only been shown to be a metric of cellularity in tumors 
(1-3), but have also been used to examine treatment response to both chemotherapy and 
radiotherapy (4,5) in preclinical and clinical settings. Based on Einstein‟s equation 
describing Brownian motion, if the diffusivity of free water at body temperature is ~ 2.5 
µm
2
/ms, within an interval of approximately 35 ms, water will move ~ 13 µm which is 
approximately the size of a cell. Thus, by adjusting the timing of a DW-MRI sequence, 
an estimation of cellularity can be determined based on the limitation placed upon 
diffusion by cellular membranes. This idea has been widely used in oncology. 
Correlations with ADC maps and tumor cellularity have been demonstrated (6-11). 
Because of its high sensitivity, DW-MRI has also been used to monitor treatment 
response in a variety of anti-cancer therapies, including both cytotoxic and anti-
vascular/anti-angiogenic drugs (4,5,12). However, the specific changes in tissue that lead 
to these changes in ADC are not fully understood but most likely involves a combination 
of changes in cellularity, tissue reorganization, and increased extracellular space 
tortuosity, as mentioned in Chapters III and VII (13). 
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Pharmocokinetic modeling of DCE-MRI data also yields a parameter that has been 
shown to reflect cellularity. In the literature, ve has been shown to correlate with cellular 
density and the extravascular, extracellular space (14-16). There are very few treatment 
studies that use ve alone to predict response (17,18), and even fewer have examined this 
parameter as it relates to other cell density metrics, such as the study done by  Yankeelov 
et al (12). In this study, DCE-MRI and DW-MRI were acquired both pre- and post-
chemotherapy treatment in order to determine the sensitivity of these two techniques in 
determining treatment response. Of particular note in this study was the finding that the 
correlation between ADC and ve was negative. While trends showing an increase in ADC 
and a decrease in ve after treatment have been reported in this study and others (8,19-21), 
this is the first study to simultaneous examine the relationship between these parameters. 
However, this finding seems counterintuitive; as a tumor is successfully treated, there is a 
reduction in cell density presumably leading to an increase in ADC and an increase in ve. 
Another study examining ADC and ve in glioblastomas found confounding results as well. 
While both ADC and ve have been assumed to be metrics of extravascular extracellular 
space, no relationship between the two parameters were found in glioblastoma 
multiforme (22); thus, a rigorous examination of both the relationship between these 
parameters and histological measures is needed. 
This study proposed to investigate the relationship between ADC and ve by the two 
aforementioned types of treatment, AZD 2171 and AZD 1480, to manipulate the 
cellularity levels within the tumor. DCE-MRI and DW-MRI imaging at different time 
points during these treatments were used to examine any spatial and temporal relationship 
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that might exist between these two imaging measures; then, endpoint imaging data were 
examined with histology data.  
 
Methods 
The same data sets acquired in the previous chapter were used for analyses in this 
study. For detailed information on tumor model, animal model, or acquisition parameters, 
see Chapter VII: Methods. 
  
Statistical Correlation Analysis 
In order to determine if any relationship exists between ADC and ve, imaging data 
were examined at two levels for correlation: spatial correlation between voxel data and 
histological correlation with immunohistochemistry findings.  
To determine if a spatial correlation exists between these two measures, sets of 
imaging data acquired from eight animals at the baseline time point were used. For each 
animal, two parametric maps containing ADC and ve data were filtered to ensure non-
physiologically relevant data were removed (e.g., 0 < ve < 1, 0 < ADC < 0.0033 mm
2
/s – 
approximately the ADC of free water at body temperature + 10%). Then, the voxel pairs 
were plotted against each other, and linear regression was used to characterize any 
relationship between the two parameters; the Pearson correlation coefficient was found 
between data sets to assess the significance of the relationship.  
Imaging data that was obtained at day 5 post-treatment (Chapter VII) were filtered to 
only include animals that had reasonable phantom/muscle data (0.0027 mm
2
/s > 
ADCphantom > 0.0033 mm
2
/s and 0 > ve > 1, with typical wash-in/wash-out characteristics 
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of muscle). These multi-slice MRI maps were examined to find a single slice that 
represented the corresponding section of the tissue slice that was stained using 
hemotoxylin and eosin (H&E) for nuclei (dark purple) and cytoplasm (light purple), 
respectively. Aperio (Vista, CA) digital histology images of the tumor were acquired at 
20× magnification. The Positive Pixel Count Algorithm, developed by Aperio, was used 
to create maps of intra- and extracellular regions based on intensity thresholding; briefly, 
based on the intensity of the stains, images were thresholded into four categories: positive 
(e.g., hemotoxylin), strong (e.g., eosin), weak (e.g., eosin), and no staining (e.g., 
extracellular regions). The percentage of extracellular (EC (%)) space was found as 
described by Eqn. (VII-1). Imaging data from the corresponding histology slice were then 
compared to this parameter to determine the relationship, if any, between ADC, ve, and 
the extracellular compartment. Linear regression parameters and Pearson correlation 
coefficients were found for 1) ve and EC, 2) ADC and EC, and 3) ADC and ve.  
 
Results 
Data acquired at baseline for eight animals were used to assess spatial correlation 
between ADC and ve. The results of a linear regression and correlation analyses are 
presented in Table VIII-1.  
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As demonstrated by the remarkably low R
2
 fit (average = 0.17), no linear relationship 
was identified between ADC and ve. Additionally, the slope was approximately 0 
(average = 1.76 × 10
-4
), reaffirming the lack of a statistical relationship between these 
two parameters. When the data sets were directly correlated using the Pearson correlation 
coefficient, R, the average R value was 0.12. Three mice (indicated by each row) are 
illustrated in Fig. VII-2 Parametric maps of ve (first column) and ADC (second column) 
were paired and plotted against each other in the scatter plot depicted in the third column. 
The black line indicates the trend line fit to the data. The examples in this figure clearly 
support the lack of direct spatial correlation between these two parameters. 
TABLE VIII-1 
SPATIAL CORRELATION OF ADC AND VE. 
ID 
M b R
2
 R 
 (× 10
-4
)  (× 10
-4
)  (fit) (data) 
1 3.50 4.80 0.36 0.36 
2 2.91 2.79 0.20 0.20 
3 2.53 6.99 0.15 0.16 
4 0.19 7.47 0.10 0.10 
5 6.29 7.47 0.18 0.04 
6 -0.34 9.30 0.02 -0.02 
7 4.26 2.93 0.25 0.25 
8 -1.29 9.65 0.14 -0.13 
Average 1.76 6.43 0.17 0.12 
STD 1.93 2.65 0.10 0.16 
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H&E data obtained from the end time point were quantified to determine the 
extracellular cellular area fraction (EC (%)); then, the appropriate imaging slice was 
matched with each histology slice and the imaging and histology parameters were plotted 
against each other as shown in Fig. VIII-3. A significant positive correlation (p = 0.007) 
was found between ADC and EC (%), demonstrated in Fig. VIII-3 (a); additionally, an 
increasing trend between ve and EC (%), shown in Fig. VIII-3 (b), was also found to be 
significant (p = 0.02).  
 
Fig. VIII-1.  Example ve (leftmost column) and ADC (center column) for three mice 
(ID # 4, 3, and 6 from Table VIII-I). Plots of ve vs. ADC for each animal are displayed 
in panels c, f and j. A trend line is shown on each scatter plot by the solid black line; 
slope and goodness of fit parameters can be found in Table VIII-1.  
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The ADC and ve values determined from the ROIs from each day 5 slice mentioned above 
were plotted against each other in Figure VIII-3. A positive linear trend is evident but no 
statistical significance (p = 0.15) was determined.  
 
Fig. VIII-2.  Panel a shows the results of comparing histology data (EC (%)) to ADC 
while panel b shows the comparison with ve. A significant correlation was found 
between both ADC and EC (%) with a p = 0.007 as well as ve and EC (%) with a p = 
0.02. 
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Discussion 
Recently, there has been a great interest in the imaging community to resolve the 
relationship between the parameters of ve and ADC. Both these parameters have been 
shown to correlate with cell density in a similar fashion, independently (13,15), but the 
relationship between the two parameters appears to dissolve in response to cancer 
treatment. In fact, in some studies that have determined a temporal correlation in 
response to treatment, it has been found to be an inversely proportional relationship 
between these two metrics (12). It has been greatly detailed in the literature that ADC is 
highly sensitive to cellular changes during treatment (4,5) but very rarely has ve been 
used as a primary metric assessing treatment efficacy.  
Interestingly, this study shows that both ADC and ve have a statistically significant 
positive correlation with the amount of extracellular space within the tumor. Since ADC 
is a reflection of the free diffusion of water, in areas of decreased cellular boundaries 
(high EC (%)), an increase in ADC is anticipated; similarly, an increase in extracellular 
 
Fig. VIII-3.  Average ADC and ve from each animal on the day 5 slice were plotted 
against each other and linear regression was used to determine any relationship. There 
was no significant correlation (p = 0.15). 
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space should yield an increase in the DCE-MRI parameter ve since it is a biomarker for 
this exact characteristic. While it is not necessarily surprising to see a significant 
relationship with these two parameters, it is surprising that ve (the fraction of 
extravascular extracellular space) is hugely overestimated compared to its histological 
counterpart. Additionally, ve showed little predictive value in terms of assessing treatment 
for AZD 1480 and AZD 2171, while ADC was able to determine that these significant 
changes in extracellular space were occurring during AZD 1480 treatment. Finally, these 
two metrics have very little spatial correlation as well, as shown in Table VIII-1. Thus, it 
seems that while both ve and ADC correlate with cell density, there may be underlying 
tumor physiology that is influencing these measurements, specifically ve. 
To examine this point even further, Fig. VIII-4 and Fig. VIII-5 demonstrate the 
parametric maps derived from imaging with the corresponding histology slice. Panel (a), 
(b), and (c) in Fig. VIII-4 show the parametric maps for K
trans
, ve and ADC overlaid on a 
T2-weighted images, while (d) is the original H&E slice with (e) indicating the 
thresholded image used to quantify EC (the white area represents the unstained regions, 
while purple, orange and yellow are thresholded stained areas separated by high, 
medium, and low intensity strength, respectively). Interestingly, the ADC map 
corresponds well with the dense cell staining in (d) and (e) as denoted by the dark purple 
(nuclei) staining (yellow arrows) as well as areas of low cell density (white/black 
arrows). 
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The maps of ve in (b) show elevated values in the area indicated by the white/black 
arrows (low density regions) but the ve distribution seems heterogeneous compared to the 
histology; note, however, that K
trans
 is low in the area with reduced cellularity. It seems 
that physiology that affects the flow and/or distribution of the CA could affect the ve 
measurement; for example, the CA may be diffusing passively into to the tumor as 
opposed to active delivery.   
Figure VIII-5 demonstrates another example of these parametric comparisons with 
histology. Panels (a) and (b) are ADC and ve maps, respectively while (c) and (d) are the 
original and thresholded stained histology slice. 
 
Fig. VIII-4.  Panels (a), (b) and (c) depict the parametric maps for K
trans 
ve, and ADC 
overlaid on a T2-weighted image. Panels (d) and (e) are the corresponding histology 
slice with original and thresholded stains, respectively. Note the area indicated by the 
white and black arrows; this area appears to have reduced cell density. The ADC map 
seems to visually compare to the histology data while both K
trans
 and ve show elevated 
values elsewhere. The yellow areas show a significantly dense area of the tumor as 
evident by the strong purple staining (nuclei) in panels d and e. Lower ve and ADC 
values are evident here. 
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As mentioned before, the ADC map corresponds well with areas of high and low cell 
staining. In this case, ve is elevated in the area of low cell density as well, as indicated 
with the white and black arrows. Additionally, the yellow arrows emphasize the 
correlation with low ADC, low ve and high cellular staining. Similar to Fig. VIII-4, there 
exists high ve values but a very heterogeneous distribution in the ve image that does not 
intuitively follow the histology information.  
 
Fig. VIII-5.  ADC and ve parametric maps are shown in panels (a) and (b), respectively 
with the corresponding histology slice (original and thresholded) shown in (c) and (d), 
respectively. The black and white arrows emphasize an area of low cellularity while 
the yellow arrows indicate a dense area of cellular/nuclear staining. 
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The significant correlation with EC (%) and the linear trend observed on an ROI 
average scale between ve and ADC such as in Fig. VIII-3, suggest that cell density does 
strongly affect ve. However, the lack of spatial correlation with ve and ADC parametric 
maps as well as the heterogeneity in the histology comparison suggests that cellular 
density or extravascular/extracellular space might not be the only factor influencing ve. 
Since ve relies on the flow of a CA into the extravascular, extracellular space, regions that 
are not well perfused or necrotic regions such as that shown in Fig. VIII-4 and Fig. VIII-
5, may misrepresent the extravascular, extracellular volume. This cell density 
measurement is based on the indirect method of quantifying the pharmacokinetics of a 
CA in tissue; thus, physiology that affects the flow and/or distribution of the CA (e.g., 
passive diffusion or active delivery of the CA) will inherently confound the ve 
measurement.  
The inability of ve to display predictive value in the study discussed in Chapter VII 
may suggest that improvement in the acquisition and/or analyses of the DCE-MRI 
data/model might be required to truly study this parameter.  One interesting finding from 
the treatment study described in Chapter VII is that some tumors exhibited unique signal 
intensity curves that never quite plateaued; this phenomenon is illustrated in Fig. VIII-6.  
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The black circle/fit line data is the muscle curve acquired from the animal while the blue 
triangle/fit line represents the tumor tissue uptake. As evident in the muscle curve, there 
is a clear uptake and wash-out in this animal, indicating a successful injection of contrast 
agent.  
While there is a possibility that some of the ve overestimation seen in Fig. VIII-3 (b) 
could be due to the use of the population derived vascular input function (discussed in 
Chapter VI), the overestimation of this magnitude indicates another underlying issue. The 
tumor appears to never reach equilibrium, even after seventeen minutes of acquisition. 
For this particular animal, the ve value returned from this fit was well over a 100% 
extravascular extracellular volume percent, which is physiologically implausible. While 
this fit returned a high R
2
 value of > 0.95, the returned fit parameters are obviously 
flawed in this particular case. By examining this signal intensity time curve, it appears 
that there is another process, other than that dictated by K
trans
, by which the contrast agent 
is entering the tumor. The gradual uptake in the latter time points of the tumor indicate 
 
Fig. VIII-6.  An example of a muscle tissue curve and corresponding fit (black) in 
comparison to a tumor tissue and fit (blue).  No plateau or wash out period is evident 
for the tumor tissue curve. 
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that contrast agent may be diffusing into the tumor from other surrounding tissue. For this 
study, spatially dependent diffusion had not been incorporated into the two compartment 
model but previous investigators have incorporated this component into the standard 
model (23).  
This study suggests that both ADC and ve are influenced by cellular density, but 
further investigation is warranted. An optimized study should be designed to allow for a 
more complete understanding of these two parameters. First, the Calu-6 model used in 
this study tend to have large areas of necroses that may confound gradual changes in 
cellular density; either a tumor model with less necroses should be chosen or care should 
be taken to use an imaging technique that accurately identifies necrotic regions that do 
not meet DCE-MRI/DW-MRI model assumptions. Additionally, a cytotoxic treatment 
such as doxorubicin, mentioned in Chapter III, is suggested to directly affect cellularity; 
the treatments used in this study were anti-angiogenic (AZD 2171) and a Jak2 inhibitor 
(AZD 1480) have an indirect effect on cellularity. In order to obtain absolute ve values 
without the possibility of overestimation, an individual vascular input function should be 
acquired for each subject in the study. A model that incorporates diffusion within the two 
compartment model should be used in order to accurately obtain true physiological 
representation of the tumor kinetics. With these amendments to protocol design, a more 
rigorous comparison between ve, ADC, and heterogeneous histology can be achieved. 
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CHAPTER IX 
 
CONCLUSION 
 
DCE-MRI techniques are one of the more commonly used measurements for 
characterizing tumor associated vasculature.  Parameters obtained using DCE-MRI are 
useful in measuring changes in tumor vascularity and cellularity in response to treatment. 
In addition, DCE-MRI studies offer quantification of the treatment response so that 
longitudinal studies of treatment might be better evaluated. The studies presented in this 
work have demonstrated the optimization of a pre-clinical DCE-MRI protocol, the 
application of two imaging techniques (DCE-MRI and DW-MRI) in longitudinally 
assessment of the efficacy of a novel anti-cancer therapy (AZD 1480), and closely 
examined the relationship between two imaging parameters that are biomarkers for 
cellular density (ADC and ve).  
This work has shown that the error associated with the population-derived VIF can be 
minimized such that a population averaged VIF can be used in a pre-clinical setting 
instead of  an individually measured VIF. Therefore, future DCE-MRI protocols can be 
modified to offer more flexibility in providing higher SNR and improved spatial 
resolution critical to examining lesion heterogeneity.  
Then, both DCE-MRI and DW-MRI were used to examine a novel Jak2 inhibitor 
compared to both a positive anti-angiogenic (AZD 2171) and vehicle controls. This work 
showed that measures of cellularity (ADC) produced from DW-MRI proved to be 
significantly more sensitive at early time points (day 3 and day 5 post-treatment) than 
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parameters reporting on the anti-angiogenic affect by DCE-MRI (K
trans
); this information 
can be potentially applied to future pre-clinical and clinical trials. 
And finally, quantitatively comparing cell density parameters produced by DCE-MRI 
(ve) and DW-MRI (ADC) with each other and with histology showed that both correlate 
significantly with changes in extracellular volume, but it also yielded the need for future 
work in DCE-MRI model development and study design to fully elucidate factors that 
affect ve.  Overall, these contributions have aided in developing appealing future studies 
in addition to improving DCE-MRI use in pre-clinical longitudinal treatment studies. 
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APPENDIX A 
 
 
 
 
Fig. A-1 Percent change in K
trans
 (a), ADC (b) and ve (c) for each individual subject in 
the AZD 1480 treatment group at baseline, day 3, and day 5 time points. The black 
horizontal line represents the group mean. 
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Fig. A-2 Percent change in K
trans
 (a), ADC (b) and ve (c) for each individual subject in 
the AZD 2171 treatment group at baseline, day 3, and day 5 time points. The black 
horizontal line represents the group mean. 
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Fig. A-3 Percent change in K
trans
 (a), ADC (b) and ve (c) for each individual subject in 
the Control treatment group at baseline, day 3, and day 5 time points. The black 
horizontal line represents the group mean. 
 
